Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS...

41
Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery 687 Pine Avenue West, S10.30 Montreal, Quebec H3A 1A1 TELEPHONE: Office - (514) 934-1934 Ext. 34042 FAX: (514) 843-1503 LANGUAGES: English, French, Bulgarian EDUCATION Post-secondary School Education and Training Dawson College, Montreal, Canada 1973-1975 Diploma of Collegial Studies, Health Sciences McGill University, Montreal, Canada 1975-1976 Faculty of Science (Pre-Med Year) McGill University, Montreal, Canada 1976-1980 Faculty of Medicine, MDCM

Transcript of Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS...

Page 1: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE

IDENTIFICATION

OFFICE ADDRESS: Royal Victoria HospitalDepartment of Surgery687 Pine Avenue West, S10.30Montreal, Quebec H3A 1A1

TELEPHONE: Office - (514) 934-1934 Ext. 34042

FAX: (514) 843-1503

LANGUAGES: English, French, Bulgarian

EDUCATION

Post-secondary School Education and Training

Dawson College, Montreal, Canada 1973-1975Diploma of Collegial Studies, Health Sciences

McGill University, Montreal, Canada 1975-1976Faculty of Science (Pre-Med Year)

McGill University, Montreal, Canada 1976-1980Faculty of Medicine, MDCM

Page 2: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

Post-Graduate Medical Education

Royal Victoria Hospital, Montreal, Canada 1980-1981Rotating Internship

Royal Victoria Hospital, Montreal, Canada 1981-1983Resident, General Surgery

McGill University, Montreal, Canada 1983-1985Royal Victoria HospitalResearch Fellow, Experimental SurgerySupervisors: Dr. Nicolas V. Christou

Dr. Jonathan L. Meakins

Royal Victoria Hospital, Montreal, Canada 1985-1987Administrative Chief Resident, General Surgery

University of Cincinnati Medical Center, Cincinati, USA 1987-1988Research Fellow, Transplantation

University of Cincinnati Medical Center, Cincinati, USA 1988-1989Clinical fellow, Transplant Surgery

University of Cincinnati Medical Center, C Cincinati, USA 1989-1990Research/Clinical Fellow, Transplant Surgery

MEDICAL LICENSES AND BOARD CERTIFICATIONS

License, New York State 1981License, Province of Quebec (81221) 1981National Board of Medical Examiners 1981LMCC 1981License, State of Florida 1982License, Province of Ontario 1982License, State of Ohio 1987Corporation Profesionelle des Medecins Specialistes du Quebec 1987Fellow of the Royal College of Surgeons of Canada (FRCS) 1987American Board of Surgery Certified 1988Amercian Board of Surgery ReCertified 1998Certificate of Competence in Transplantation Surgery 1989University of CincinnatiLicense, State of Vermont 2003

APPOINTMENTS

Page 3: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

University

Assistant Professor of Surgery 1990-1996McGill University

Associate Professor of Surgery, Tenured 1996-PresentMcGill University

Hospital

Assistant Surgeon 1990-1996Royal Victoria HospitalGeneral Surgery, Transplantation, Surgical Intensive Care Unit

Director, Liver Transplant Program 1990-1998Royal Victoria Hospital

Assistant Surgeon 1991-PresentMontreal Children’s HospitalLiver and Kidney Transplantation

Assistant Surgeon 1991-PresentSte. Justine HospitalLiver and Kidney Transplantation

Assistant Surgeon 1995-PresentMontreal General HospitalGeneral Surgery, Transplantation

Associate Surgeon 1996-PresentRoyal Victoria HospitalGeneral Surgery, Transplantation, Surgical Intensive Care Unit

Surgical Director of Transplantation 1998-2003McGill University Health Center

Assistant Surgeon 2003-PresentFletcher Allen Health CareGeneral Surgery, Transplantation

Director of Multi-Organ Transplantation Program 2003-2006McGill University Health Center

Director of Kidney Transplantation 2003–Present McGill University Health CenterRoyal Victoria Hospital

Page 4: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

Director of Live Donor Transplantation 2007-PresentMcGill University Health CenterRoyal Victoria Hospital

Surgical Director of Transplantation Pediatrics 2007-PresentMcGill University Health CenterMontreal Children’s Hospital

ACADEMIC AWARDS AND HONORS

McGill University Entrance Scholarship 1975

Royal Victoria Research Institute Scholarship 1984

Johnson & Johnson Fellowship 1987The Surgical Infection Society

John Armour Fellowship 1992-1994

Chercheur Boursier Scholar (Quebec) 1993-1999

Lifetime Recognition Award for Organ Donation & Transplantation 2008Quebec Transplant

INVITED LECTURES AND PRESENTATION

McGill University

1. McGill University Health Center, Multidisciplinary Surgical Grand Rounds, “What’s New in Transplantation?” Montreal, PQ, January 29, 2004.

2. McGill University Health Center - Back to Basics Seminar – Montreal, PQ – March 2004 - “Clinical Immunology in Transplantation”.

Abroad1. Visiting Professor. Dept.of Surgery, St.Luke’s Medical Center. ‘Controversies in Indications for

Liver Transplantation.’1993.

2. Visiting Professor. Dept.of Surgery, New England Medical Center, Tuft’s University, Surgical Grand Rounds. ‘Hepatitis B Liver Cirrhosis is an indication for Liver Transplantation.’ Boston, MA 1996.

Page 5: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

3. Invited Speaker. Quebec Association of General Surgeons. ‘Update on Liver Transplantation and Hepatitis B.’ Manoir Richelieu, 1998.

4. Invited Speaker, Center for Clinical Immunology and Transplantation. ‘Update in Liver Transplantation.’ 1998.

5. Invited Speaker. International Molecular Farming Conference. Hepatic Xenotransplantation: ‘Fulminant hepatic failure a window of opportunity.’ 1999.

6. Invited Speaker. Quebec Transplant Association. ‘Long term outcome of hepatitis C liver transplant recipients under different immunosuppression’. London, ON, 2001.

7. Visiting Professor. Dept.of Surgery, Emory University - Atlanta, Georgia. ‘Induction Therapy and Renal Function in Liver Transplant Patients’. 2002.

8. Invited Speaker. Fujisawa Investigator Coordinator Meeting. ‘Update on Hepatitis C, Results in Liver Transplantation’. Toronto, ON. 2002.

9. Visiting Professor. Dept.of Surgery University of Vanderbilt, Nashville, TN. ‘The Impact of Renal Function in Liver Transplantation.’ 2002.

10. Invited Speaker, Genzyme Liver Investigator Meeting. ‘Use of Thymoglobulin in Liver Transplant Patients; Implications with Hepatitis C and Renal Function.’ New Orleans, Louisiana, 2004.

11. Invited Speaker. Genzyme Training Meeting, ‘Liver Transplantation: What’s New and Challenging’. Boston, MA. 2004

12. Invited Speaker. Transplant Fellows Workshop, Canadian Transplant Congress. ‘Hepatitis C Recurrence’. Mont-Tremblant, QC. 2004.

13. Invited Speaker, Societe quebecoise de transplantation. ‘Expanded Criteria Donors’. Quebec City, QC, 2004.

14. Invited Speaker, 5th Annual Canadian Transplant Forum, Canadian Transplant Society. ‘Cadaveric Renal Transplantation and Expanded Criteria donors’. Vancouver, BC. 2004

15. Invited Speaker. ‘Use of Expanded Criteria Donors in Renal Transplant Patients; McGill Experience’, Jamaica, January 2004.

16. Visiting Professor. Transplantat Surgery, McMaster University,‘Utilization of Expanded Criteria Donor Kidneys: Are we doing enough?’ Hamilton, ON, 2005

17. Presentation, Annual Renal Transplant Forum, Canadian Transplant Congress. ‘Expanded Criteria Donor; The McGill Experience’. Banff, AB, March 2005.

Page 6: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

18. Presentation, Annual Liver Transplant Study Group, Canadian Transplant Congress. ‘Acute Liver Transplant Survival and MELD score; The McGill Experience’. Banff, AB, March 2005.

19. Visiting Professor. Transplant Surgery, University of British Columbia, ‘Optimizing the use of cadaveric kidneys: a Canadian experience’. Vancouver, BC, 2005.

20. Visiting Professor. Transplantat Surgery, University of Alberta, ‘Optimizing the use of cadaveric kidneys: a Canadian experience’. Edmonton, AB, 2005.

21. Invited Speaker, Schering ‘Update from Speaker’s Bureau in Nevada’, Montreal, QC, April 2005.

22. Invited Speaker, Schering ‘Update on HCV screening and treatment’, Montreal, QC April 2005

23. Invited Speaker, Novartis Annual Forum on Immunological Pathways in Transplantation. ‘Calcineurin Sparing Protocols in Organ Transplantation’. Madrid, Spain, April 2005.

24. Invited Speaker, Annual Forum on Immunological Pathways in Transplantation. ‘Calcineurin Sparing Protocols in Organ Transplantation’. Basel, Switzerland, April 2005.

25. Invited Speaker, Societe quebecoise de transplantation, ‘Hepatitis B and liver transplantation: 12 years experience. Review of post liver transplant treatment of hepatitis C’. Quebec City, October 2005.

26. Visiting Professor. Dept of Surgery, Dalhousie University. ‘Antithymocyte Globulin Induction Therapy in Hepatitis C positive Liver Transplant Recipients’. Halifax, NS, 2005.

27. Visiting Professor. Dept of Surgery, Massachusetts General Hospital, Harvard Medical School. ‘Induction Therapy in Liver Transplantation patients’. Boston, MA, 2005.

28. Visiting Professor. Dept of Medicine, Dalhousie University. ‘Calcineurin Sparing Protocols in Organ Transplantation’. Halifax, NS, 2006.

29. Visiting Professor. Dept of Surgery. Westchester Medical Center, New York Medical College. ‘Polyclonal Antibody in Liver Transplant’. Westchester, NY, 2006.

30. Visiting Professor. Transplant Surgery, The Lahey Clinic. ‘Thymoglobulin in Liver Transplantation’. Burlington, MA, 2006.

31. Visiting Professor. Dept of Surgery, Vancouver General Hospital, University of British Columbia. ‘Induction Therapy in Liver Transplantation; Indications and Rational’. Vancouver, BC, 2007.

32. Invited Speaker. The Transplantation Society New Key Opinion Leader Meeting 2007, ‘Expanded Criteria Donors in Kidney Transplantation’, Montreal, Quebec, 2007.

Page 7: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

33. Visiting Professor. LifeLink and Tampa General Hospital. ‘Impact of Thymoglobulin on Renal Function and Calcineurin Inhibitor Initiation in Recipients of Liver Transplants’, Tampa, FL. 2007.

34. Visiting Professor. TransLife, Florida Hospital Orlando. ‘Impact of Thymoglobulin on Renal Function and Calcineurin Inhibitor Initiation in Recipients of Liver Transplants’, Orlando, FL. 2007.

35. Visiting Professor. Transplant Surgery. Indiana University, School of Medicine. “Xenoantibody and ABO incompatibility: Similarities in B cell activation and antibody production.” Indianapolis, Indiana, December 2008.

36. Invited Speaker. XIXth Annual Conference of the Bulgarian Association of Surgeons, Gastroenterologists and Oncologists. “Early post operative complications after liver transplantation.” Sofia, Bulgaria, May 2009.

OTHER CONTRIBUTIONS

Pharmaceutical Advisory Board & Other

1. Wyeth Pharmaceuticals, Second Annual Dialogues in Transplantation. Toronto, ON, June 2005.2. Novartis Canada, Physician Transplant Advisory Board. Toronto, ON. February 20053. Novartis Canada, Renal Transplantation Advisory Board Meeting. Toronto, ON, November 2005.4. Genzyme Canada, National Thymoglobulin Advisory Board Meeting. Toronto, ON, December

2006.5. Canadian Council for Donation and Transplantation Concensus Forum ‘Enhancing Living

Donation’. Vancouver, BC, February 2006.6. Canadian Council for Donation and Transplantation Concensus Forum ‘Enhancing Living

Donation’. Toronto, ON, March 2006.7. Astellas, The Canadian Liver Transplant Forum: Deceased Donor Liver Allocation in Canada: Is it

time for a change? Assessing the role of MELD/PELD, Montreal, QC, October 20068. Novartis Canada, Renal Transplantation Advisory Board – Toronto, ON - November 3-4, 2006.9. Genzyme Canada, 2nd National Thymoglobulin Advisory Board. Toronto, ON, April 27, 2007.10. Genzyme Cananda, National Liver Advisory Board for Thymoglobulin and the Transplant Division.

Toronto, ON, May 26, 2007.11. 3rd Annual Canadian Liver Transplant Forum. Toronto, ON, November 13, 2007.12. Astellas, 8th Renal Transplant Forum. Montreal, QC, November 2007.13. Medical Council of Canada, Physician Examiner LMCC. October 26, 200814. Canadian Blood Services, National Stakeholder concenses on Organ and Tissue Donation and

Transplantation. Hull, QC October 2008.15. Society Quebec de transplantation & Society Francais de Transplantation. Chaired Session. Quebec

City, QC, October 2008.16. Medical Council of Canada, Physician Examiner LMCC. May 3, 2009

Clinical, Scientific & Ethics Review

Page 8: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

1. Review of Scientific Merit, MUHC Research Institute. Analysis of Colorectal Cancer Metastases to the liver by tissue microarray. Principle Investigator: Peter Metrakos, MD – November 2007.

2. Review of Scientific Merit, MUHC Research Institute. Association between Helicobater pylori infection and disease severity in hepatitis B, hepatitis C and non alcoholic fatty liver disease (NAFLD). Principle Investigator: Marc Deschenes, MD – December 2007.

3. Grant Review The Kidney Foundation of Canada: Tolerance Induction through targeting memory T cells in presensitized recipients of kidney allografts. Montreal, QC, 2007.

4. Manuscript Peer Review. Annals of Surgery. “Intrahepatic cholangiocarcinoma: Rising frequency, improved survival and determinants of outcome after resection.” ANNSURG-D-07-01122 - January 2008.

5. Grant Review; Canadian Liver Foundation: A Prospective, Randomized Trial to Investigate the Effects of Glucose /Ischemic Preconditioning Donor Pre-treatment on Reperfusion Injury in Deceased-Donor Liver Transplantation. Montreal, QC May 2008.

6. Manuscript Peer Review. Canadian Journal of Surgery: “Kidney and Liver Transplants from donors after Cardiac Death: Initial Experience at London Health Sciences Centre.”CJS-0011-08-OA –November 2008.

7. Review of Scientific Merit, MUHC Research Institute. Glucose/Insulin Clamp for Solid Organ Transplants (Liver, Kidney and Pancreas): A pilot project. Principle Investigator: Peter Metrakos, MD – December 2008.

8. Review of Scientific Merit, MUHC Research Institute. A Phase II Study of Sorafenib in Combination with TheraSphere in Advanced Hepatocellular Carcinoma. . Principle Investigator: Peter Metrakos, MD – February 2009.

9. Review of Scientific Merit, MUHC Research Institute. Dextrose/Insulin clamp for solid organ transplant (heart, liver, kidney and pancreas) on cadaveric donors. Principle Investigator: Peter Metrakos, MD – May 2009.

10.

RESEARCH1. Research Activities:

a) Past: 1) Altered host resistance as measured by delayed type hypersensitivity skin testing in malnourished and burn trauma induced animals as a predictor of immune response: Correlation with susceptibility to bacterial infection and phagocytic cell delivery to inflammatory sites.

Page 9: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

b) Current: 1) The Role of donor specific transfusion in Tolerance induction in vascularized solid organ transplantation.

2) Donor cell trafficking following donor specific transfusion and the role of the Thymus in allograft Tolerance. Characterization of the phenotype of donor cell trafficking through the thymus following donor leukocyte injection and characterization of the lymphokines activated during this process.

3) The effect of intra-portal vein donor specific transfusion on small bowel and other vascularized allograft survival.

4) Characterization of endothelial cell injury in healthy and in liver failure patients and characterization of the difference in sinusoidal versus aortic endothelial cells in xenograft models ( Pig, Human, Dog, Rat, Guinea Pig, etc.)

5) Prevention of recurrence of Hepatitis B virus after Liver transplantation in patients with Hepatitis B Liver cirrhosis.

6) Dog to Pig xenotransplantation model - characterization of the hyperacute xenograft rejection in liver and kidney dog to pig model, a prelude to clinical xenograft transplantation.

7) Endothelial cell activation in an in-vitro xenotransplantation model ‘Pig to Human’.

8) B cell response to xenoantigens.

Research Supporta) Personal Support.

John Armour Fellowship -Donor Specific Transfusion and tolerance Induction 1992-1994 - $30,000.00

Fonds en Recherche Scientifique du Quebec (FRSQ)-Donor Specific Transfusion and Tolerance Induction 1992-1998 - $34,000.00/year (Total $ 192,000.00)

b) Research Grants.Canadian Association of General Surgeons - Donor Specific Transfusion and Tolerance Induction 1990 1991 - $ 10,000.00

Page 10: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

Royal Victoria Research Institute- Donor Specific Transfusion and Tolerance Induction. 1990-1992 - $65,000.00

Canadian Red Cross Society Operating Grant-The use of alpha-interferon pre transplant and HBIg Immunoprophylaxis Post Transplant to prevent HBV recurrence in HBV-DNA positive Liver Cirrhosis patients- 1995-1997 - $80,000.00.

Royal Victoria Hospital Research Institute Grant – Effect of Pamidronate followed by Alendronate on prevention of bone loss after orthotopic liver transplantation. Co-Investigator (PI-Dr. R. Kremer)

c) Pharmaceutical-Industry Support.Sandoz Canada Pharmaceuticals- Multicenter Trial of Neoral vs Sandimmune Cyclosporine in primary adult liver transplant candidates 1994-1995 - $200,000.00

Sandoz Canada Pharmaceuticals-Conversion to Sandimmune-Neoral ®

from Sandimmune cyclosporine ® in stable liver transplant patients 1995 -$15,000.00

Sangstat Pharmaceuticals- Retrospective analysis in the use of Thymo-Globulin (TMG) as induction immunosuppression in Liver transplant recipients 1995 - $23,000.00

Schering-Plough Pharmaceuticals- The use of Intron A ® in Hepatitis B positive Liver cirrhosis patients in reducing viral load pre-transplant and preventing Hepatitis B recurrence after liver transplantation when combined with HBIg post-transplant.- 1995-1996 - $ 40,000.00

Fujisawa Canada - Characterization of Liver Xenograft rejection in small animal and large animal models- Research Fellowship support (Dr. Joseph Tector) - 1995-1996- $40,000.00

Fujisawa Canada - Multi Center Canadian Trial - Comparison of Prograf (FK 506) versus Sandimmune- Neoral in primary liver allografts - 1996-1997- .

Fujisawa Canada – Grant – Dog to Pig xenotransplantation model. Co-investigator Joseph Tector, MD - $100,000.

Page 11: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

Fujisawa Canada – Grant – Pig to Human endothelial cell activation in in-vitro xenotransplantation model.- $100,000 – 2003.

Fujisawa Canada – Grant – B cell activation in a xenotransplantation model - $100,000 – 2004.

Fujisawa Canada – Grant – Organ Survival after Transplantation with High-Risk Donor Kidneys - $100,000. – 2005.

Roche Pharmaceuticals – Grant – Multi-Organ Tranpslant Database -$50,000.00 – 2005.

TEACHING

1. McGill Courses:Division of Surgical Research- Course No.: 519-604 BSeminars in Surgical Research- From the bench to the bedsideTransplantation Immunosuppression and Tolerance 1991-

Division of Clinical Immunobiology and TransplantationSeminars in TransplantationLiver Transplantation: Surgical, Medical, and Immunosuppressive considerations 1994-

2. Small Group TeachingPortal hypertension, liver cirrhosis, and acute liver failurePhase III McGill University Medical Students 1997-

Abdominal and Thoracic TraumaPhase III McGill University Medical Students 1993-Link McGill University Medical Students in Surgery Tutor 1991-

Case Presentation and one on one TutorLink McGill University Medical Students 1991-

Hepatology weekly seminars and Journal Club at University level 1995-

Transplantation Monthly Seminars and Journal Club 1993-

MedSpecs - MUHC International Shadowing Program 2009

3. Continuing Medical Education CoursesAnnual Refresher Course in Critical Care - McGill University1. 1994-Gastrointestinal Hemorrhage2. 1995 Fulminant Hepatic Failure.3. 1999 Fulminant Hepatic Failure.

Page 12: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

Master Class Presentation Skills, Brussels 2005- Sponsored by Novartis CanadaOptimizing Clinical Research in Transplantation 2005- American Society of Transplantation

4. Clinical Teaching

SICU attending - 1-3 hours per day - 7 day weeks - 8 weeks per year Surgical and Medical Residents and Medical Students rotating through the SICU- In context of full-time clinical care (20%).

Transplantation - Total care of liver transplant patients since 1990- 15% of time of care of 105 liver transplants in teaching residents and medical students.

Transplantation - Total care of renal transplant patients since August 1995 - 15% of time of care of 20 renal transplants teaching residents.

Transplantation - Teaching Liver and renal transplants to Senior residentsin the operating room and teaching general surgical and transplant specific operative skills to senior residents in abdominal organ retrieval and transplantation since 1990.

General Surgery - 4 hours per week in general surgical rounds teaching of junior and senior residents and medical students when attending cases in the operating room.

5. Research Trainees Supervised

Andrew Gyopar MD 1990-1991Gassan Baslaim MD 1991-1992Shafquat Ahmed MD 1992-1994Annie Fecteau MD, M.Sc. ( with F. Guttman MD) 1990-1992Title of Thesis: “ Donor specific transfusion and cyclosporine in small bowel transplantation”Tioshi Takara MD (with F. Guttman MD) 1992-1994Joseph Tector MD, PhD 1994-1997Title of Thesis:“ Dog to Pig Liver Transplantation: Characterization of a preclinical xenotransplantation liver transplantation model.”Stephen Tahta MD (with C. Tchervenkov, MD) 1995-1996Nahil Elias MD 1994-1996Junia Hayashi MD (with F. Guttman MD) 1995-1997Jonathan Fridell MD, MSc 1996-1998Title of thesis:

Page 13: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

“ Characterization of pig anti-dog xenoantibodies and target xenoantigens on dogendothelial cells and dog platelets.”Jonathan Hakim MD 1998-1999Antonio Di Carlo MD 1998-2000Title of Phd Thesis: “Endothelial cell activation in in-vitro xenotransplantation model”Reza Tavana, MD, MSc 2005-2008Title of M.Sc Thesis:Theodora Kandeva, MSc 2005-2008Title of M.Sc Thesis:“Humoral response to carbohydrate antigens in the context of ABO incompatible transplantation and xenotransplantation.”

ADMINISTRATIVE DUTIES

1990-Present Animal care committee: The Research Institute of The Royal Victoria Hospital.

1991-Present The Medical and Surgical Ethics Committee of the Royal Victoria Hospital.

1992-1993 Infection control committee of the Royal Victoria Hospital1990-Present Director and Surgeon-in-charge Liver Transplantation Program- McGill

University.1992-Present McGill University Representative on The Executive Committee of Quebec

Transplant 1992-Present McGill University Representative on The Canadian Liver Transplantation

Association1995-1998 Director of Transplantation Services, The Royal Victoria Hospital.

1995-1997 College des Medecins du Quebec. Task force committee on evaluation of donor patterns in Quebec Hospitals.

1998-2003 Surgical Direction of Transplantation at McGill University2001–Present Division of General Surgery, Executive Committee

McGill University Health Center2001–2004 General Surgery Residency Committee

McGill University Health Center2003–Present Director Multi-Organ Transplantation Program at McGill University 2003-Present CARMS Committee Selection board2003–Present McGill University Representative on the Kidney Foundation of Montreal2008-2009 MUHC PPP – Adult Clinics and Day Hospitals Committee2009 MUHC PPP - RFP Launch - Adult Ambulatory Committee

MEMBERSHIP OF CLINICAL SOCIETIES

1988 Fellow of the Royal College of Physicians and Surgeons of Canada

Page 14: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

1988 Canadian Association of General Surgeons1990 Canadian Society of Transplantation 1990 American Society of Transplantation1991 Surgical Infection Society1991 Society for Critical Care Medicine1991 American Medical Association1993 American Society of Transplant Physicians1994 American Society of Transplant Surgeons1996 American Association for the Study of Liver Disease.1997 The Transplantation Society1998 Fellow of the American College of Surgeons1999 Society of University Surgeons2004 Canadian Association for the Study of the Liver 2008 American Hepatopancreatobiliary Association

PUBLICATIONS

1. Tchervenkov JI, Diano E, Meakins JL, Christou NV: The effect of burn injury and sepsis on host defense. Ann Roy Coll Phys Surg 17:320, 1984.

2. Tchervenkov JI, Diano E, Christou NV: The effect of cyclosporine on host defense. Can J Surg28:525-528, 1985.

3. Tchervenkov, JI, Diano E, Meakins JL, Christou NV: Susceptibility to bacterial sepsis: accurate measurement by the delayed-type hypersensitivity skin test score. Arch Surg 121:37-40, 1986.

4. Nohr CW, Tchervenkov JI, Meakins JL, Christou NV: Malnutrition and humoral immunity: short term acute nutritional deprivation. Surgery 98:769:776, 1986.

5. Nohr CW, Tchervenkov JI, Meakins JL, Christou NV: Malnutrition and humoral immunity: long-term protein deprivation. J Surg Res 40:432:437, 1986.

6. Tchervenkov JI, Latter DA, Psychogios J, Lisbona R, Christou NV: Decreased phagocytic cell deliver to inflammatory lesions is due to the host "trauma environment" not to intrinsic cellular defects. Surgical Forum 27:90-92, 1986.

7. Tchervenkov JI, Latter DA, Meakins JL, Christou NV: Altered leukocyte delivery to specific and non-specific inflammatory sites after trauma. J Trauma 28:582-588, 1988.

8. Tchervenkov, JI, Latter DA, Meakins JL, Christou NV: The influence of long term malnutrition of phagocytic cell delivery to inflammatory lesions. Surgery 103:463-469, 1988.

9. Tchervenkov JI, Epstein MD, Silberstein EB, Alexander JW: Early burn wound excision and skin grafting restores the in vivo neutrophil delivery to inflammatory lesions. Arch Surg 123:1477-1481, 1989.

Page 15: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

10. Tchervenkov JI, Epstein MD, Alexander JW, Schroeder TJ: The effect of donor specific transfusion, cyclosporine and dietary prostaglandin precursor on rat cardiac allograft survival II. Effectiveness of a 24-hour induction period with DST and CSA in inducing long-term graft survival. Transplantation 47:177-181, 1989.

11. Epstein MD, Tchervenkov JI, Alexander JW, Inoue S, Kuroiwa K, Jacobs P: Effect of intraluminal antibiotics on translocation of Candida Albicans in burned guinea pigs. Burns 16:105-108, 1990.

12. Ogle CK, Tchervenkov JI, Alexander JW, Palkert D, Taylor A, Barnwell S, Ogle JD, Warden GD: The effect of high lipid diet on in vitro prostaglandin E2 production of splenic macrophages. JPEN14:250-254, 1990.

13. Tchervenkov JI, Munda R: An alternative technique of anastomosis of multiple renal arteries in the transplant patient. Transpl Int. 3:116-7, 1990.

14. Kuroiwa K, Trocki O, Alexander JW, Tchervenkov JI, Inoue S, Nelson JL: Vitamin A supplementation in enteral formulas for burned guinea pigs. BURNS 50:883-884, 1990.

15. Brunson ME, Ing R, Tchervenkov JI, Alexander JW: Variable infection risk following allogeneic blood transfusions. J Surg Res 48:308-312, 1990.

16. Tchervenkov JI, Munda R, Weiss M, First RM: Adult respiratory distress syndrome following chronic rejection of pancreatic allograft: a case report. Transplantation 50:883-884, 1990.

17. Sridhar NR, Tchervenkov JI, Weiss M, Nagasi Y, First MR: Disseminated histoplasmosis in a renal transplant patient: a cause of renal failure several years following transplant. Am J Kid Dis.17:719-721, 1991.

18. Brunson ME, Tchervenkov JI, Alexander JW: Enhancement of allograft survival by donor-specific transfusion one day prior to transplant: importance of timing and specificity when DST is given with cyclosporine. Transplantation 52:545-549, 1991.

19. Epstein MD, Tchervenkov JI, Alexander JW, Johnson R, Veter R: Increased gut permeability immediately post burn trauma. Arch Surg. 126:198-200, 1991.

20. Cofer BR, Tchervenkov JI, Alexander JW, Barnwell SC: Donor-specific transfusion and cyclosporine prolong allograft survival when given in the peroperative period. Transplant Proc. 23:157-158, 1991.

21. Fisher RA, Tchervenkov JI, Schroeder TJ, Alexander JW, First MR: Efficacy of induction therapy in cadaveric renal transplantation comparing rabbit antithymocyte serum and Minnesota antilymphoblast globulin. Transplant Proc. 23:1253-1255, 1991.

Page 16: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

22. Brunson ME, Tchervenkov JI, Cofer BR, Alexander JW, Babcock GF: Partial T-cell depletion with monoclonal antibody improves the enhancing effect of donor specific transfusion plus cyclosporine. Transplant Proc. 23:307-308, 1991.

23. Ryckman FC, Flake AW, Fisher RA, Tchervenkov JI, Pederson SH, Balistreri WF. Segmental orthotopic hepatic transplantation as a means to improve patient survival and diminish waiting list mortality. J. Pediatr Surg. 26:422-428, 1991.

24. Shroeder TJ, Pesce AJ, Ryckman FC, Brunson ME, Pedersen SH, Tchervenkov JI, Penn I, Alexander JW, Balistreri WF. Selection criteria for liver transplant donors. J Clin Lab Anal. 5: 275-277, 1991.

25. Fecteau A, Tchervenkov JI, Rosenman E, Guttman FM. Small bowel transplantation in the rat: The effect of donor specific transfusion and low dose cyclosporine. Transplant Proc. 24:1166, 1992.

26. Cofer BR, Davies CB, Alexander JW, Tchervenkov JI, Fisher RA. Effects of pre- and postengraftment donor specific transfusions and cyclosporine on the enhancement of experimental allograft survival. J Surg Res. 52:663, 1992.

27. Cofer BR., Davies CB., Alexander JW, Tchervenkov JI.. The effect of the prostaglandin analogs mysoprostil and enisoprost on the synergy between donor specific transfusion and cyclosporine in allograft survival. Transplantation 54:941-943, 1992.

28. Fecteau A, Tchervenkov JI, Guttman FM, Takara T, Mayer S, Lubin A, Rosenman E. Intraportal donor-specific transfusion 24hours pretransplant with cyclosporin is effective in prolonging small bowel transplant survival. Surg Forum 43:619, 1992.

29. Gyopar A, Loertscher R, Guttmann R, Tchervenkov JI. Comparison between donor specific whole blood, bone marrow, and spleen leukocytes on allograft survival when combined with cyclosporine. Transplantation 55:1199-1202, 1993.

30. Cantarovich M, Tchervenkov JI, Loertscher R. Transplantation of kidneys from a donor with Nisseria meningitis infection. Am J Neph. 55:1199-1202, 1993.

31. Tchervenkov CI, Shum-Tim D, Serrick CJ, Gyopar A, Lough JO, Tchervenkov JI. The effect of primary xenograft or allograft on the rejection of a subsequent allograft. Transplant Proc. 25: 453-454, 1993.

32. Gianotti L, Munda R, Alexander JW, Tchervenkov JI, Babcock GF. Bacterial translocation: a potential source for infection in acute pancreatitis. Pancreas 8:551-558, 1993.

33. Takara T, Tchervenkov JI, Guttman FM, Fecteau A. Kuppfer cell inhibition with gadolinium abrogates the beneficial effect of intraportal vein donor specific transfusion given 24 hours before small bowel transplantation. Surg Forum 44:635-638, 1993.

Page 17: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

34. Ahmed S, Baslaim G, Guttmann RD,Tchervenkov JI. Effect of transfusion with donor specific peripheral lymphocytes, whole blood or erythrocytes on cardiac allograft survival in cyclosporine treated rats. Transplantation 57:634-637, 1994.

35. Fecteau A, Tchervenkov JI, Guttman FM, Takara T, Rosenman E. Small bowel transplantation: The effect of intraportal donor-specific transfusion 24 hours pretransplant and low dose cyclosporin. Transplantation 58:399-402, 1994.

36. Takara T, Tchervenkov JI, Guttman FM, Fecteau A, Rosenman E. Intraportal donor specific transfusion given 24hours before small bowel transplantation with cyclosporine and FK506. Transplant Proc. 26:1622, 1994.

37. Berger KJ, Schreiber RA, Tchervenkov J, Kopelman H, Brassard R, Stein L. Decompression of portal hypertension in a child with cystic fibrosis after transjugular intrahepatic portosystemic shunt placement. J Pediatr Gastroenterol Nutr. 19:322-325, 1994.

38. Ahmed SM, Tector JA, Zheng SX, Forbes C, Tchervenkov JI. The intact thymus is necessary to induce cardiac allograft prolongation with intravenous donor lymphocytes and cyclosporine. Surg Forum 45:411-414, 1994.

39. Tchervenkov JI, Cofer BR, Davies C, Alexander JW. Indefinite allograft survival induced by the synergistic interaction of multiple donor specific transfusions, cyclosporine, and an anti-T-cell monoclonal antibody in a protocol relevant to cadaveric organ transplantation. The importance of a prolonged posttransplant cyclosporine coverage. Transplantation 59:821-824, 1995.

40. Tchervenkov JI, Tector JA, Cantarovich M, Tahta SA, Asfar A, Naimi J, Elias N, Barkun JS. Maintenance immunosuppression using cyclosporine monotherapy in adult orthotopic liver transplant recipients. Transplant Proc. 28: 2247-2249, 1996.

41. Tector AJ, Elias N, Rosenberg L, Soderland C, Naimi J, Dugud WP, and Tchervenkov JI. Mechanisms of resistance to injury in pig livers perfused with blood from patients in liver failure. Transplant Proc. 29: 966-969, 1997.

42. Tchervenkov JI, Flemming C, Guttman RD, des Gachons G. Use of thymoglobulin induction therapy in the prevention of acute graft rejection episodes following liver transplantation. Transplant Proc. 29(7A): 13S-15S, 1997.

43. Ibebunjo C, Donati F, Fox GS, Eshelby D, and Tchervenkov JI. The effect of Chronic tacrinetherapy on D-tubocurarine blockade in the soleus and tibialis muscles of the rat. Anesth Anal 1997.

44. Ibebunjo C, Eshelby D, Donati F, Fox GS, and Tchervenkov JI. Tacrine does not alter the potency of succinylcholine in the rat. Can J Anesth 44: 1021-1026, 1997.

45. Tchervenkov JI, Tector AJ, Barkun JS, Sherker A, Forbes CD, Elias N, Cantarovich M, Cleland P, Metrakos P, Meakins JL. Recurrence-free long term survival following liver transplantation for

Page 18: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

hepatitis B using interferon-alpha pre-transplant and hepatitis B immune globulin post-transplant. Annals of Surgery; 226: 356 - 368, 1997.

46. Keyser EJ, Ahmed NA, Mott BD, and Tchervenkov JI. Double closed loop obstruction and perforation in a previous Roux-en-Y gastric bypass. Obesity Surgery; 8: 475-479, 1998.

47. Cantarovich M, Barkun JS, Forbes RDC, Kosiuk J, Tchervenkov JI. Successful treatment of post-transplant lymphoproliferative disorder with interferon-alpha and intravenous immunoglobulin. Clinical Transplantation: 12; 109-115, 1998.

48. Cantarovich M, Barkun JS, Tchervenkov JI, Besner JG, Aspeslet L, Metrakos P. Comparison of neoral dose monitoring with cyclosporine trough levels versus 2-hour post-dose levels in stable liver transplant patients. Transplantation; 8: 1621-1627, 1998.

49. Cantarovich M, Barkun JS, Besner JG, Metrakos P, Alpert E, Deschenes M, Aalamian Z, Tchervenkov JI. Cyclosporine peak levels provide a better correlation with the area-under-the-curve than trough levels in liver transplant patients treated with neoral. Transplant Proceedings; 30: 1462-1463, 1998.

50. Cantarovich M, Barkun JS, Besner JG, Metrakos P, Alpert E, Deschenes M, Aalamian Z, Tchervenkov JI. Optimal time points for the prediction of the area-under-the-curve in liver transplant patients receiving tacrolimus. Transplant Proceedings; 30: 1460-1461, 1998.

51. Roy A, Grant DR, Kneteman NM, Tchervenkov JI, Levy GA, Tan A, Hendricks L. A comparative randomized prospective multicenter study of Sandimmune versus neoral in liver transplantaion. Annales de Chirurgie; 52: 716-721, 1998.

52. Tector AJ, Chen X, Soderland C, Tchervenkov JI. Complement activation in discordant hepatic xenotransplantation. Xenotransplantation; 5: 257-261, 1998.

53. Tector AJ, Fridell JA, Watanabe T, Forbes C, Salazar J, Grienke D, Nuera S, Metrakos P, Giaid A, and Tchervenkov JI. Pulmonary injury in recipients of discordant hepatic and renal xenografts in the dog-to-pig model. Xenotransplantation; 5: 44-49, 1998.

54. Grant D, Kneteman N, Tchervenkov JI, Roy A, Murphy G, Tan A, Hendricks L, Guilbault N, Levy G. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune from liver transplantation (NOF-8). Transplantation; 8: 1133-1137, 1999.

55. Deschenes M, Forbes RDC, Tchervenkov JI, Barkun JS, Metrakos P, Tector AJ, and Alpert E. The use of old donor livers is associated with more extensive ischemic damage on the intraoperative biopsies during liver transplantation. Liver Transplantation and Surgery; 5: 357-361, 1999.

56. Tector AJ, Fridell JA, Watanabe T, Forbes C, Salazar J, Grienke D, Nuera S, Metrakos P, Giaid A, and Tchervenkov JI. Experimental discordant hepatic xenotransplantation in the recipient with

Page 19: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

liver failure: Implications for clinical bridging trials. Journal of the American College of Surgeons; 191: 54-64, 2000.

57. Baldry C, Backman SB, Metrakos P, Tchervenkov JI, Barkun JS, Moore A. Liver Transplantation in a Jehova’s Witness with ankylosing spondylitis. Canadian Journal of Anesthesia; 47: 642-646, July 2001.

58. Morin N, Lamoureux E, Lipman M, Tector J, Tchervenkov JI, Metrakos P. Donor-specific portal transfusion augments microchimerism in a porcine model of small bowel transplantation. Transplantation Proceedings; 32: 1290-1291, 2000.

59. Tector AJ, Berho M, Fridell JA, Di Carlo A, Liu S, Soderland C, Barkun JS, Metrakos P, Tchervenkov JI. Rejection of pig liver xenografts in patients with liver failure: implications for xenotransplantation. Liver Transplantation; 7: 82-89, 2001.

60. Zaltzman J, McAlister V, Russel D, Halloran P, Landsberg D, Busque S, Shoker A, Boucher A, Shapiro J, Tchervenkov JI, Peets J. Tacrolimus, MMF, steroid and ALG immunotherapy for high immunological risk renal transplant recipients. Transplantation Proceedings; 33: 1044-1045, 2001.

61. Tchervenkov JI, Metrakos P, Deschenes M, Alpert E, Tector AJ, Cantarovich M, Barkun JS. Decreasing viral load pre-transplant and passive immunoprophylaxis with hepatitis immunoglobulin post-transplant prevents hepatitis B virus recurrence after liver transplantation: an 8-year single center experience. Transplantation Proceedings; 33: 1514-1515, 2001.

62. Di Carlo A, Tector AJ, Liu S, Tan M, Barkun JS, Soderland C, Metrakos P, Tchervenkov JI. Activation of porcine hepatic microvascular sinusoidal endothelial cells in pig-to-human liver xenotransplantation. Transplantation Proceedings; 33: 759-761, 2001.

63. Tan M, Di Carlo A, Robinson P, Tchervenkov JI, Barkun JS, Metrakos P. Successful outcome after transplantation of a donor liver with focal nodular hyperplasia. Liver Transplantation; 7: 652-655, 2001.

64.Tan M, Di Carlo A, Stein L, Tchervenkov JI, and Metrakos P. The pseudoaneurysm of the superior mesenteric artery after pancreas transplant treated by endovascular stenting: a case report and literature review. Transplantation; 72: 336-338, 2001.

65. Deschenes M, Michel RP, Alpert E, Barkun JS, Metrakos P, Tchervenkov JI. Elevation of CA-125 level is due to abdominal distension in liver transplantation candidates. Transplantation; 72: 1519-1522, 2001.

66. Tan M, Di Carlo A, Liu SQ, Tector AJ, Tchervenkov JI, Metrakos P. Hepatic sinusoidal endothelium upregulates IL-1alpha, INF-gamma, and iNOS in response to discordant xenogenic islets in an in vitro model of xenoislet transplantation. Journal of Surgical Research; 102: 229-236, 2002.

Page 20: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

67. Seely AJ, Naud NF, Campisi G, Giannias B, Liu S, Di Carlo A, Ferri L, Pascual JL, Tchervenkov JI, Christou NV. Alteration of chemo-attractant receptor expression regulates human neutrophil chemotaxis in vivo. Annals of Surgery; 235: 550-559, 2002.

68. Shan W, Backman S, Barkun J, Metrakos P, Tchervenkov J. Blood Product use during Hepatic Transplant. Canadian Journal of Anesthesia. 49:71A 2002.

69. Tzimas G, Barkun J, Metrakos P, Tchervenkov J. Aberrant right hepatic artery; A mockery. Liver Transplantation. 8(4):411, 2002.

70. Cantarovich M, Metrakos P, Giannetti N, Cecere R, Barkun J, Tchervenkov JI. Anti-CD25 monoclonal antibody coverage allows for calcineurin inhibtor “holiday” in solid organ transplant patients with acute renal dysfunction. Transplantation; 73: 1169-1172, 2002.

71. Greig P, Lilly L, Scudamore C, Erb S, Yoshida E, Kneteman N, Bain V, Ghent C, Marotta P, Grant D, Wall W, Tchervenkov J, Barkun J, Roy A, Marleau D, McAlister V, Peltekian K. Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up. Liver Transplantation. 9(6):587-95, 2003.

72.Chan G, Tchervenkov J, Cantarovich M, Alpert E, Deschenes M, Ergina P, Metrakos P, Barkun J, Veno-atrial bypass for the operative treatment of septic gas gangrene secondary to delayed hepatic artery thrombosis. American Journal of Transplantation. 3(6):760-3, 2003.

73. Cantarovich M, Tzimas GN, Barkun J, Deschenes M, Alpert E, Tchervenkov J, Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction. Transplantation. 76(1):98-102, 2003.

74. Tzimas G, Hayati H, Tchervenkov JI, Metrakos P. Ureteral implantation technique and urologic complications in adult kidney transplantation. Transplantation Proceedings, 35(7): 2420-2422, 2003.

75. Barkun J, Tzimas G, Cantarovich M, Metrakos P, Deschenes M, Alpert E, Paraskevas S, Tchervenkov JI. Do biliary endoprotheses decrease biliary complications after liver transplantation? Transplantation Proceedings, 35(7): 2435-2437, 2003

76. Shan W, Barkun J, Metrakos P, Tchervenkov J, Backman S. Blood Product use during Orthotopic Liver Transplantation. Canadian Journal of Anesthesia. 51: 1045-1046, 2004.

77. Bergman S, Feldman LS, Carli F, Anidjar, Metrakos P, Tchervenkov J, Paraskevas S, Klassen D, Vassiliou M, Andrew C, Stanbridge D, Fried G. Convalescence after laparoscopic live donor nephrectomy. American Journal of Transplantation, (S8):369, 2004

78. Cantarovich M, Barkun J, Giannetti N, Cecere R, Besner J-G, Tchervenkov JI. History of C2

monitoring in heart and liver transplant patients treated with cyclosporine microemulsion. Transplantation Proceedings, 36(2) : S442-S447, 2004.

Page 21: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

79. Tzimas G, Deschenes M, Barkun J, Wong P, Tchervenkov JI, Hayati H, Alpert E, Metrakos P. Leukoreduction and acute rejection in liver transplantation: An interium analysis. Transplantation Proceedings, 36(6); 1760-1762, 2004.

80. Horton P, Deschenes M, Metrakos P, Barkun J, Cantarovich M, Tchervenkov JI. Conversion from a Replicating to a non-replicating State Prevents HBV-Recurrence in Liver Transplant Patients. Transplantation, 78(2); 1:701-702 2004.

81. Sciff J, Tchervenkov JI, Paraskevas S, Barkun J, Mangel R, Deschenes M, Fontaine G, Coursol C, Keith D, Metrakos P, Cantarovich M. Accuracy of Cimetidine-Corrected Serum Creatinine, Creatinine Clearance and Calculated Creatinine Clearance to Assess the Glomerular Filtration Rate in Long-term Kidney-Pancreas and Liver Transplant Patients. Transplantation, 78(2); 1:504, 2004.

82. Schiff J, Horton P, Tchervenkov JI, Paraskevas S, Keith D, Metrakos P, Barkun J, Mangel R, Deschenes M, Fonatine G, Cantarovich M. Differences in Pharmacokinectic Profiles between Long-term Liver and Kidney/pancreas Transplant Patients Receiving Maintenance Tacrolimus and Mycophenolate Mofetil. Transplantation, 78(2); 1:477 July 2004.

83. Horton P, Deschenes M, Metrakos P, Barkun J, Cantarovich M, Tchervenkov JI. Incidence of Chronic Renal Failure in Liver Transplant Patients using Induction with Thymoglobulin and Delay in the Introduction of Calcineurin Inhibitors. Transplantation, 78(2); 1:380-381 July 2004.

84. Tchervenkov JI, Cantarovich M, Paraskevas S, Fernandez M, Baran D, Mangel R, Schiff J, Lipman M, Horton P, Metrakos P. Cadaveric Renal Transplantation and Expanded Criteria Donors: Should we reassess their use? Transplantation, 78(2); 1:90, July 2004.

85. Tchervenkov J, Tzimas G, Cantarovich M, Barkun J, Metrakos P. The impact of Tymoglobulin on renal function and calcineurin inhibitor initiation in recipients of orthotopic liver transplant: a retrospective analysis of 298 consecutive patients. Transplantation Proceedings, 36(6): 1747-1752, 2004.

86. V Mardigyan, J Tchervenkov, P Metrakos, J Barkun, M Deschenes, M Cantarovich. Best Single Time Points as Surrogates to the Tacrolimus and Mycophenolic Acid Area Under the Curve in Adult Liver Transplant Patients Beyond 12 months of Transplantation. Clinical Therapeutics 27(4): 463-469, April 2005.

87. J Zaltman, A Boucher, S Busque, P Halloran, D Landsberg, V McAlister D Russell, A Shoker, J Shapiro, J Tchervenkov, R Ferguson. A prospective 3 yr evaluation of tacrolimus-based immunosuppressive therapy in immunological high-risk renal allograft recipients. Clinical Transplantation 19:26-32, 2005.

88. P Horton, J Tchervenkov, T Znajda, JB Martinie, P Chaudhury, C Rochon, J Barkun, P Metrakos. Antithymocyte globulin induction therapy in hepatitis C positive liver transplant recipients. Journal of Gastrointestinal Surgery, 9(7): 896-902, 2005.

Page 22: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

89. C Rochon, P Metrakos, J Tchervenkov, M Fernandez, S Paraskevas, J Barkun, M Deschenes, L Stein. Endoscopic stenting as first-line treatment in duct Lushka leaks after choledochocystic anastomosis in two cases of liver transplantation. Transplantation 79(6): 740-1, 2005.

90. D Keith, A deMattos, M Golconda, J Prather, M Cantarovich, S Paraskevas, J Tchervenkov, D Norman. Factors associated with improvement in deceased donor renal allograft function in the 1990’s. Journal of the American Society of Nephrology 16(5):1512-21, 2005.

91. J. Schiff, S. Paraskevas, D. Keith, J. Tchervenkov, P. Metrakos, M. Cantarovich. Prediction of the glomerular filtration rate using equations in kidney-pancreas transplant patients receiving cimetidine. Transplantation. 81(3): 469-72, 2006.

92. A Roy, N Kneteman, L Lilly, P Marotta, K Peltekian C Scudamore, J Tchervenkov. Tacrolimus as Intervention in the Treatment of Hyperlipidemia after Liver Transplantation. Transplantation –Multi-center study. 82(4): 494-500, 2006.

93. P Horton, P, Chaudhury, C Rochon, P Metrakos, J Tchervenkov. Should trial of liver xeno transplantation proceed in toxic fulminant hepatic failure. Xenotransplantation. 13(6): 483 2006.

94. D. Keith, M. Cantarovich, S. Paraskevas, J. Tchervenkov. Recipient age and risk of chronic allograft nephropathy in primary deceased donor kidney transplant. Transpl Int. 19(8):649-56, 2006.

95. S. Hanley, S. Liu, M. Lipsett, M. Castellarin, L. Rosenberg, J. Tchervenkov, S. Paraskevas. Tumor necrosis factor-alpha production by human islets leads to post isolation cell death. Transplantation. 2006 Sep 27; 82(6):813-8.

96. G Tzimas, K Vali, M Deschenes, V Marcus, J Barkun, J Tchervenkov, P Metrakos. Liver transplantation for metastases from bile duct carcinoid. HPB (Oxford). 2006;8(1):67-68.

97. K Han, GN Tzimas, J Barkun, P Metrakos, J Tchervenkov, N Hilzenrat, P Wong, M Deschenes. Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation. Can J Gastroenterol. 2007 Jan; 21(1): 39-45.

98. S Bergman, A Feifer, L Feldman, L Bell, H Flageole, J Tchervenkov, M Anidjar, D Stanbridge, G Fried. Laparoscopic live donor nephrectomy: The pediatric recipient in a dual-site program. Pediatr Transplantation 2007 Jun; 11(4): 429-32.

99. D Raju, M Cantarovich, M Brission, J Tchervenkov, M Lipman. Primary hyperoxaluria: clinical course, diagnosis, and treatment after kidney failure. Am J Kidney Dis. 2008 Jan; 51(1):e1-5

100.D. Keith, M. Cantarovich, S. Paraskevas, J. Tchervenkov. Duration of dialysis pretransplantation is an important risk factor for delayed recovery of renal function following deceased donor kidney transplantation. Transplt Int. 2008 Feb; 21(2):126-32

Page 23: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

101.S Bergman, L Feldman, M Anidjar, S Demyttenaere, F Carli, P Metrakos, J Tchervenkov, S Paraskevas G Fried. “First, do no harm”: monitoring outcomes during the transition from open to Laparoscopic live donor nephrectomy in Canadian center. Can J Surg. 2008 Apr;51(2):103-10.

102.M Hassanain, J Tchervenkov, M Cantarovich, P Metrakos, S Paraskevas, D Keith, D baran, M Fernandez, R Mangel, P Chaudhury. Delayed graft function has an equally bad impact on deceased donor renal graft survival in both standard criteria donors and expanded criteria donors. Transplant Proc. 2009 Jan-Feb;41(1):133-4

103.M Hassanain, J Tchervenkov, M Cantarovich, P Metrakos, S Paraskevas, D Keith, D baran, M Fernandez, R Mangel, P Chaudhury. Recovery of graft function early post transplant determines long-term graft survival in deceased donor renal transplants. Transplant Proc. 2009 Jan-Feb;41(1):124-6.

104.S Lui, T Kandeva, J Tchervenkov. CDIC-Mediated interactrion between activated T cells and B cells is essential to B cell proliferation and anti-<alpha>-gal antibody production. Transplant Proc. 2009 Jan-Feb;41(1):398-402.

105.Birnbaum LM, Lipman M, Paraskevas S, Chaudhury P, Tchervenkov J, Baran D, Herrera-Gayol A, Cantarovich M. Management of chronic allograft nephropathy: a systemic review. Clin J Am Soc Nephrol. 2009 Apr;4(4):860-5. Epub 2009 Apr.

106.R Azhar, M Boutros, M Hassanain, G Polyhronopoulos, T Cabrera, P Chaudhury, J Tchervenkov. A Rare Case of Obstructive Uropathy in Renal Transplantation: Ipsilateral Indirect Inguinal Herniation of a Transplant Ureter. Accepted for publication in Transplantation as a Letter to the Editor. May 2009.

CHAPTERS

1. Tchervenkov JI, Christou NV: Infection immunology. In: Immunology essentials of surgical practice. LH Toledo-Pereyra ed. P.S.G. Publishing Co, Inc., Littleton, MA, 1988.

2. Tchervenkov JI, Meakins JL: Surgical infection and altered host defense mechanism. In: Infection in Surgical Practice. Eric W. Taylor ed. Oxford University Press, Oxford University Press, New York, 1992.

3. Tchervenkov JI, Meakins JL: Altered host defense mechanisms in septic patients. In : Surgical Infections. Donald E. Fry ed. Little, Brown and Company, Boston, MA, 1994.

ABSTRACTS

1. Tchervenkov J, Dianno E, Meakins JL, Christou NV: The effect of burn injury and sepsis on host defense. Ann Roy Coll Phys Surg 17:320, 1984.

Page 24: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

2. Christou NV, Tchervenkov JI, Nohr CW, Buffone V, Meakins JL, MacLean LD: The delayed-type hypersensitivity skin test score measures the non-specific immune inflammatory component of host defense. Thirty-first Congress Intern. Soc.. Surgery, p. 207, 1985.

3. Tchervenkov JI, Diano E, Meakins JL, Christou NV: The delayed type hypersensitivity skin test accurately measures susceptibility to bacterial sepsis. Surgical Infection Society, 6th annual meeting, New Orleans, April 1985.

4. Nohr CW, Tchervenkov JI, Meakins JL, Christou NV: Burn injury alters humoral immunity. Clin Invest Med 8:(3)A227, 1985.

5. Nohr CW, Tchervenkov JI, Meakins JL, Christou NV: Nutritional manipulation alters humoral immunity. Clin Invest Med 8:(3)A118, 1985.

6. Latter DA, Tchervenkov JI, Nohr CW, Psychogios J, Christou NV: Indomethacin in burn injury immunosuppression. Clin Invest Med 8:(3)A117, 1985.

7. Latter DA, Tchervenkov JI, Nohr CW, Psychogios J, Christou NV: Indomethacin in burn injury immunosuppression. Academic Association of Surgery, Cincinnati,Nov 1985.

8. Nohr CW, Tchervenkov JI, Meakins JL, Christou NV: Nutritional depletion and replenishment alters humoral immunity. The Association for Academic Surgery, Cincinnati OH, 1985.

9. Tchervenkov JI, Latter DA, Lisbona R, Psychogios J, Christou NV: Delayed type hypersensitivity and bacterial infection mechanisms of leukocyte delivery. Clin Invest Med 8:(3)A138, 1985.

10. Latter DA, Tchervenkov JI, Psychogios J, Christou NV: Cell infiltrate vs function in the delayed hypersensitivity reaction (DTH). Clin Invest Med 8:(3)A178, 1985.

11. Tchervenkov JI, Latter DA, Meakins JL, Christou NV: Inflammatory cell delivery (ICD) to delayed hypersensitivity and bacterial lesions in burn trauma. Clin Invest Med 8:A178, 1985.

12. Tchervenkov JI, Latter DL, Phychogios J, Lisbona R, Christou NV: Decreased phagocytic cells delivery to inflammatory lesions is due to the host environment not to intrinsic cellular defects. Clin Invest Med 9:C547, 1986.

13. Tchervenkov JI, Diano E, Meakins JL, Christou NV: The delayed-type hypersensitivity skin test score accurately measures susceptibility to bacterial sepsis. J Crit Care , 1986.

14. Latter DL, Tchervenkov JI, Psychogios J, Christou NV: Altered neutrophil delivery to specific and non-specific inflammatory sites after trauma. Clin Invest Med 9:A174, 1986.

Page 25: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

15. Tchervenkov JI, Epstein MD, Silberstein EB, Alexander JW: Early burn wound excision and skin grafting restores the in vivo neutrophil delivery to inflammatory lesions. Surgical Infection Society, 8th annual meeting, San Francisco, 1989.

16. Epstein MD, Tchervenkov JI, Alexander JW, Inoue S, Kuroiwa K: The effect of antibiotics on translocation of Candida Albicans in burn trauma. Clin Invest Med 11:(4), (R136) 1988.

17. Tchervenkov JI, Epstein MD, Alexander JW. Donor specific transfusion and cyclosporine act synergistically on cardiac allograft survival. Clin Invest Med 11:(4) (R721) 1988.

18. Tchervenkov JI, Epstein MD, Alexander JW, Schroeder TJ: The effect of early pre-transplant donor specific transfusion (DST), low dose cyclosporine (CYS), and dietary prostaglandin precursor on cardiac allograft survival. American Society of Transplant Surgeons Fourteenth Annual Meeting, May 1988.

19. Ryckman FC, Schroeder TJ, Brunson ME, Tchervenkov JI, Pedersen SH, Penn I, Alexander JW, Balistreri WF. Pediatric liver allograft recipients require close monitoring of lymphocyte subsets to ensure proper OKT3 dosing. First International Basic Sciences Symposium of The Transplantation Society, Lake Louise, Alberta, October 1989.

20. Tchervenkov JI, Brunson ME, Alexander JW, Cofer BR, Schroeder TJ, Barnwell S: The effect of an anti-T-cell monoclonal antibody (OX52), donor specific transfusion (DST), and cyclosporine on allograft survival. American Society of Transplant Physicians Ninth Annual Meeting, May 1990.

21. Epstein ME, Tchervenkov JI, Alexander JW, Johnson JR, Vester J: Increased gut permeability immediately post burn trauma. Surgical Infection Society Tenth Annual Meeting, June 1990.

22. Cofer BR, Tchervenkov JI, Alexander JW, Barnwell SC: Donor-specific transfusion and cyclosporine prolong allograft survival when given in the peroperative period. International Transplant Society, San Francisco, August 1990.

23. Tchervenkov JI, Brunson ME, Alexander JW, Schroeder TJ, First MR, Fisher RA, Munda R: Starting cyclosporine pretransplant reduces rejection episodes and improves allograft function in living related haplotype mismatched renal transplant patients. American Society of Nephrologists, Annual Meeting, Washington DC, December 1990.

24. Tchervenkov JI, Munda R, Alexander JW, Cofer BR, Fisher RA, First MR: Kidneys from high risk donors should be considered for transplantation. American Society of Transplant Physicians, 9th Annual Meeting, Chicago, May 1990.

25. Fisher RA, Tchervenkov JI, Schroeder TJ, Alexander JW, First MR: Efficacy of induction therapy in cadaveric renal transplantation comparing rabbit antithymocyte serum and Minnesota antilymphoblast globulin. International Transplant Society, San Francisco, August 1990.

Page 26: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

26. Brunson ME, Tchervenkov JI, Cofer BR, Alexander JW, Babcock GF: Partial T-cell depletion with monoclonal antibody improves the enhancing effect of donor specific transfusion and cyclosporine. International Transplant Society, San Francisco, August 1990.

27. Tchervenkov, JI: Effects of Cyclosporin A and Genistein on 5-lipoxygenase metabolite(s) of archidonic acid from human mononuclear cells. American Society of Transplant Physicians, Chicago Il, 1991

28. Tchervenkov JI, Cofer B, Alexander JW, Barnwell S, Davies C, Fischer R. Indefinite allograft survival induced by donor specific transfusions, cyclosporine, and an anti-T cell monoclonal antibody: a protocol relevant to cadaveric transplantation. First Symposium on Tolerance Induction, Breckenridge, Colorado 1991.

29. Cofer BR, Davies CB, Tchervenkov JI, Alexander JW. Abrogation of cyclosporine/donor specific transfusion induced immunosuppression by 5-lipoxygenase inhibition. First Symposium on Tolerance Induction, Breckenridge, Colorado 1991.

30. Cofer BR, Fisher RA, Davies CB, Tchervenkov JI, Alexander JW: Effects of multiple postransplant donor specific transfusions (DST) and cyclosporine (CsA) in prolonging experimental allograft survival. Tolerance Induction, Breckenridge, Colorado, 1991.

31. Tchervenkov CI, Shum-Tim D, Serrick CJ, Gyopar A, Lough JO, Tchervenkov JI. The effect of primary xenograft or allograft on the rejection of a subsequent allograft. International Transplant Society, Paris 1992.

32. Gyopar A, Loertscher R, Guttmann R, Tchervenkov JI. Comparison between donor specific whole blood, bone marrow, and spleen leukocytes on allograft survival when combined with cyclosporine. American Society of Transplant Physicians,Annual Meeting, Chicago 1992.

33. Baslaim G, Ahmad S, Ashelby D, Tchervenkov JI. The synergy between donor specific transfusion 24hrs pretransplant and cyclosporine (CsA). Is the DST 24hrs pretransplant really necessary? Third symposium on tolerance induction. Breckenridge, 1993.

34. Ahmed SM, Baslaim G, Guttmann RD, Tchervenkov JI. The beneficial effect of the synergy between donor specific transfusion 24hrs pre-transplant and cyclosporine resides in the lymphocyte fraction of whole blood. Third symposium on tolerance induction. Brackenridge, 1993.

35. Ahmed SM, Baslaim G, Guttmann RD, Tchervenkov JI. Superior cardiac allograft survival using donor specific peripheral lymphocytes vs whole blood or erythrocytes given 24hrs pretransplant concomitant with cyclosporine. American Society of Transplant Physicians, Annual Meeting, Houston 1993.

36. Tchervenkov JI, Ahmed SM, Barkun JS, Cleland P, Guttmann RD, The use of alpha-interferon pretransplantation and polyclonal-hepatitis B gamma globulin post-transplantation to prevent recurrence of hepatitis B virus re-infection in HBV cirrhosis patients. Annual Meeting of the

Page 27: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

Canadian Transplant Society, Toronto 1994.

37. Ahmed SM, Zheng S, Forbes RDC, Tchervenkov JI. Thymectomy abrogates cardiac allograft prolongation in rats treated intravenously with donor antigen and cyclosporine. Annual Meeting of the Canadian Transplant Society, Toronto 1994.

38. Takara T, Guttman FM, Tchervenkov JI: Intraportal donor specific transfusion prevents fatal graft versus host disease seen in small bowel allograft induced with combination FK506 and cyclosporine and prolongs allograft survival. Tolerance Induction, Breckenridge, 1995.

39. Ahmed SM, Eshelby D, Tector JA, Zheng S, Forbes RDC, Tchervenkov JI: The importance of recipient thymus and spleen in mediating allograft prolongation induced by donor antigen and cyclosporine in an adult rat model. Tolerance Induction, Breckenridge, 1995.

40. Tchervenkov JI, Tector AJ, Sherker AH. Pretransplant interferon, posttransplant hepatitis B immunoglobulin, and rapid taper of immunosuppression prevents posttransplant recurrence of hepatitis B. American Association for the Study of Liver Diseases. Single topic Symposium “Liver Transplantation for Chronic Viral Hepatitis”, Reston Virginia, March 1995.

41. Takara T, Tector AJ, Guttman FM, Rosenman E, Tchervenkov JI. Intraportal donor specific transfusion prevents fatal graft versus host disease seen in small bowel allografts induced with combination FK506 and cyclosporine and prolongs allograft survival. American Society of Transplant Surgeons, Annual Meeting, Chicago 1995.

42. Ahmed SM, Eshelby D, Tector JA, Zheng S, Forbes RDC, Tchervenkov JI: The importance of recipient thymus and spleen in mediating allograft prolongation induced by donor antigen and cyclosporine in an adult rat model. American Society of Transplant Surgeons, 21st Annual Meeting, Chicago 1995.

43. Tchervenkov JI, Tector AJ, Tahta SA, Asfar A, Naimi J, Barkun JS: Maintenance immunosuppression using cyclosporine monotherapy in orthotopic liver transplant adult recipients. Cybercongress - Transplantation in the next Millennium, Washington DC, November 1995.

44. Tector, AJ, Elias N, Ahmed SM, Paraskevas S, Fridell J, Fouad FM, Mamer OA, Barkun JS, Rosenberg L, Tchervenkov JI. Ex-vivo pig liver perfusion as a bridge to liver transplant. The Third Int. Congress for Xenotransplantation, Boston MA, September 1995.

45. Tchervenkov JI, Tector J, Elias N, Barkun JS, Cantarovich M, Alpert E, Forbes C, Sherker A. Recurrence-free long-term survival following liver transplantation for hepatitis B using Interferon Alpha pre-transplant and hepatitis B immune globulin (Hbig) post-transplant. 15th Annual Meeting of the American Society of Transplant Physicians, Dallas TX, May 1996.

46. Cantarovich M, Tchervenkov JI, Laneuville P, Kosiuk J, Latter D, Barkun J. Successful treatment of post-transplant lymphoproliferative disorder (PTLD) with Interferon-Alpha (INF) and

Page 28: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

intravenous gamma-globulin (Ig). 15th Annual Meeting of the American Society of Transplant Physicians, Dallas TX, May 1996.

47. Tchervenkov JI, Tector AJ, Barkun JS, Tahta SA, Cantarovich M, Alpert E. Maintenance immunosuppression using Cyclosporine (CY) monotherapy in orthotopic liver transplant (OLT) adult recipients is possible in most patients. 15th Annual Meeting of the American Society of Transplant Physicians, Dallas TX, May 1996.

48. Tahta SA, Tector AJ, Cohen D, Elias N, Eshelby D, Forbes RDC, Tchervenkov C, Tchervenkov JI. Delayed xenograft rejection: Characterization of mechanism and effect of T and B cell immunosuppression in a discordant model. 15th Annual Meeting of the American Society of Transplant Physicians. Dallas TX, May 1996.

49. Tector AJ, Elias N, Rosenberg L, Soderland C, Duguid WP, and Tchervenkov JI. Why are pig livers perfused with the blood of patients in liver failure resistant to hyperacute rejection. 22nd

Annual Meeting of the American Society of Transplant Surgeons. Dallas TX, May 29-31, 1996.

50. Tchervenkov JI, Tector AJ, Fridell J, Cleland P, Sherker AH, Metrakos P, Alpert E, Barkun JA. Orthotopic liver transplantation for hepatitis B cirrhosis is a superior indication to hepatitis C: a single center experience. 23rd Annual Meeting Scientific Meeting of the American Society of Transplantation Surgeons. Chicago IL, May 14-16,1997.

51. Tchervenkov JI, Tector AJ, Metrakos P, Barkun J, Elias N, Sherker A, Cleland P. Recurrence-free long term survival following liver transplantation for hepatitis B using Interferon alpha pre transplantation and hepatitis B immunoglobulin post transplantation. 117th Annual Meeting of The American Surgical Association. Quebec City, April 17-19, 1997.

52. Tchervenkov JI, Metrakos P, Barkun J, Cantarovich M, Deschênes, Alpert E, Tector AJ, Fridell J, Aalamian Z. Rejection rate and the cost of maintenance immunosuppression is reduced when using Tacrolimus compared to Neoral® based immunosuppression in liver transplant recipients: A single center experience. The International Congress on Immunosuppression, Orlando FL, December 1997.

53. Cantarovich M, Fridell J, Besner JG, Barkun J, Metrakos P, Deschênes M, Alpert E, Aalamian Z, Tchervenkov JI. Optimal time points for the prediction of the area-under-the-curve in liver transplant patients receiving Tacrolimus. The International Congress on Immunosuppression, Orlando FL, December 1997.

54. Cantarovich M, Barkun J, Besner JG, Metrakos P, Alpert E, Deschênes M, Aalamian Z, Tchervenkov JI. Cyclosporine peak level provides a superior correlation with the area-under-the-curve than trough levels in liver transplant patients treated with Neoral. The International Congress on Immunosuppression, Orlando FL, December 1997.

55. Cantarovich M, Barkun JS, Metrakos P, Deschênes M, Alpert E, Aalamian Z, Tchervenkov JI. Ajustement de la dose de Neoral avec des niveaux de cyclosporine 2-heures après la dose matinale:

Page 29: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

effet sur la dose et la fonction rénale après transplantation hépatique. Société Québecoise de Néphrologie, Congrès Annuel, April 1998.

56. Cantarovich M, Barkun J, Aspeslet L, Halloran P, Aalamian Z, Tchervenkov JI. Relationship between Calcineurin activity and Cyclosporine pharmacokinetics in stable liver transplant patients treated with Neoral. American Society of Transplant Physicians, Chicago IL, May 1998.

57. Cantarovich M, Barkun J, Besner JG, Metrakos P, Deschênes M, Alpert E, Aalamian Z, Tchervenkov JI. Cyclosporine 2-hour blood level: An excellent predictor of the area-under-the-curve in liver transplant patients treated with Neoral. American Society of Transplant Physicians, Chicago IL, May 1998.

58. Cantarovich M, Barkun J, Metrakos P, Deschênes M, Alpert E, Tchervenkov JI. Clinical benefit of Neoral dose monitoring with Cyclosporine 2-hour peak levels compared to trough levels in stable liver transplant patients. American Society of Transplant Physicians, Chicago IL, May 1998.

59. Tchervenkov JI, Metrakos P, Barkun J, Tector AJ, Morin N, Cantarovich M, Deschenes M, Alpert E. Maintenance Immunosuppression with Cyclosporine Monotherapy in Liver Transplant Adult Recipients. American Society of Transplant Surgeons, Chicago IL, May 1998.

60. Deschênes M, Forbes C, Barkun J, Alpert E, Cantarovich M, Metrakos P, Fernandez M, Tchervenkov J. The use of older donor livers is associated with more severe preservation injury following liver transplantation. Digestive Disease Week, New Orleans, May 1998.

61. Tchervenkov J, Metrakos P, Barkun J, Tector J, Morin N, Cantarovich M, Deschênes M, Alpert E. Maintenance immunosuppression with cyclosporine monotherapy in liver transplant adult recipients. XVII World Congress of the Transplantation Society. Montreal, July 1998.

62. Tchervenkov JI, Barkun J, Metrakos P, Tector J, Cleland P, Deschênes M, Alpert E, CantarovichM. Interferon alpha or lamivudine prior to lilver transplant and hepatitis B immunoglobulin posttransplant prevents hepatitis B recurrence. XVII World Congress of the Transplantation Society. Montreal, July 1998

63. Cantarovich M, Barkun J, Metrakos P, Deschênes M, Alpert E, Tchervenkov J. Clinical benefit of Neoral dose monitoring with cyclosporine 2-hr post-dose levels compared to trough levels in stable liver transplant patients. XVII World Congress of the Transplantation Society. Montreal, July 1998, and 2è Congrès de la Société Francophone de Transplantation, Bruges, Belgium, December 1998

64. Deschenes M, Barkun JS, Cantarovich M, Alpert E, Metrakos P, Fernandez M, and Tchervenkov JI. Liver transplantation in patients over 65 years of age: Mortality, morbidity and quality of life. American Association for the Study of Liver Disease, Chicago IL, November 1998.

65. Tector AJ, Chen XW, Soderland C, Fridell JA, and Tchervenkov JI. Complement activation in discordant hepatic xenotransplantation. American Association for the Study of Liver Disease, Chicago IL, November 1998.

Page 30: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

66. Tchervenkov JI, Metrakos P, Barkun JS, Cantarovich M, Deschenes M, Alpert E, Tector AJ, Fridell JA, and Aalamian Z. Rejection rate and cost of maintenance immunosuppression is reduced when using Tacrolimus compared to Neoral based immunosuppression in liver transplant recipients. American Association for the Study of Liver Disease, Chicago IL, November 1998.

67. Tector AJ, Fridell JA, Watanabe T, Metrakos P, and Tchervenkov JI. Dog-to-Pig hepatic xenotransplantation: A suitable large animal model for the pursuit of clinical pig-to-human liver transplants. American Association for the Study of Liver Disease, Chicago IL, November 1998.

68. Fridell JA, Mak A, Liu S, Jensen G, and Tchervenkov JI. The resistance of the hepatic xenograft to hyperacute rejection is at the level of the sinusoidal endothelial cell: Studies in the dog-to-pig model. American Association for the Study of Liver Disease, Chicago IL, November 1998.

69. Tector AJ, Fridell JA, Greinke D, Salazar J, Metrakos P, and Tchervenkov JI. Discordant hepatic xenotransplantation in recipients with liver failure: A window of opportunity for clinical trials. American Association for the Study of Liver Disease, Chicago IL, November 1998.

70. Goulet L, Barkun JS, Metrakos P, and Tchervenkov JI. Donor identification and retrieval rate at a major university medical center in Canada. Canadian Association of Transplantation, Lake Louise AB, March 1999.

71. Tector AJ, Fridell JA, Di Carlo A, and Tchervenkov JI. Immunopathology of pig livers used in clinical ex-vivo xenoperfusions: Acute vascular rejection. American Society of Transplant Surgeons, Chicago IL, May 1999.

72. Cantarovich, M, Barkun JS, Deschenes M, Metrakos P, Tchervenkov JI. Improvement of renal dysfunction secondary to cyclosporine in long-term liver transplant patients receiving mycophenolate mofetil and very low dose Neoral. American Society of Transplantation, Chicago, IL. May 2000.

73. Zaltzman JS, McAlister V, Russell D, Halloran PF, Landsberg DN, Busque S, Shoker A, Boucher A, Tchervenkov JI, Shapiro J, Peets J. Tacrolimus, MMF, steroid and ALG immunotherapy for high immunological risk renal transplant recipients. American Society of Transplantation, Chicago, IL. May 2000.

74. Di Carlo A, Tector AJ, Tan M, Fridell JA, Liu S, Soderland C, Barkun JS, Metrakos P, and Tchervenkov JI. Comparison of cytokine profiles of endothelial activation in aortic and hepatic models of xenotransplantation. American Society of Transplantation, Chicago, IL. May 2000.

75. Greig PD, Grant DR, Knetemen NM, McAlister VC, Roy AF, Scudemore CH, Tchervenkov JI, Wall WJ, Yoshida EM. Early steroid withdrawal following liver transplantation-Two year follow up. American Society of Transplantation, Chicago, IL. May 2000.

76. Di Carlo A, Tector AJ, Tan M, Fridell JA, Liu S, Barkun JS, Metrakos P, Tchervenkov JI. Endothelial activation results in upregulation of interleukin-1 and endothelin-1 mRNA in pig-to-

Page 31: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

human liver xenotransplantation. XVIII International Congress of the Transplant Society, Rome Italy, August 2000.

77. Di Carlo A, Tector AJ, Tan M, Fridell JA, Liu S, Barkun JS, Metrakos P, Tchervenkov JI. Comparison of cytokine profiles of endothelial cell activation in aortic and hepatic models of xenotransplantation. XVIII International Congress of the Transplant Society, Rome Italy, August 2000.

78. Zaltzman JS, McAlister V, Russell D, Halloran P, Landsberg D, Busque S, Shoker A, Boucher A, Tchervenkov JI, Shapiro J, Peets J. Tacrolimus, MMF, steroid and ALG immunotherapy for high immunological risk renal transplant recipients the Canadian multi-center high-risk renal transplant study. XVIII International Congress of the Transplant Society, Rome Italy, August 2000.

79. Tchervenkov JI, Cantarovich M, Metrakos P, Deschenes M, Alpert E, Tector AJ, Barkun JS. Decreasing viral load pre-transplant and passive immunoprophylaxis with hepatitis B immunoglobulin post-transplant results in complete prevention of hepatitis B virus recurrence after liver transplant: a seven year experience. XVIII International Congress of the Transplant Society, Rome Italy, August 2000.

80. Cantarovich M, Barkun JS, Deschenes M, Metrakos P, Tchervenkov JI. Improvement of renal dysfunction secondary to cyclosporine in long-term liver transplant patients receiving mycophenolate mofetil and very low dose neoral. XVIII International Congress of the Transplant Society, Rome Italy, August 2000.

81. Di Carlo A, Tan M, Liu S, Metrakos P, and Tchervenkov JI. Endothelial activation results in upregulation of interleukin-1A and endothelin-1 MRNA in pig-to-human liver xenotransplantation. Royal College of Physician and Surgeons Annual Meeting, Edmonton, AB, September 2000.

82. Deschênes M, Barkun J, Cantarovich M, Alpert E, Metrakos P, Tchervenkov J. Corticosteosteroid treatment of late acute cellular rejection is associated with worst recurrent hepatitis C virus hepatitis after liver transplantation than treatment of early acute cellular rejection. American Society Liver Diseases, Dallas, October 2000.

83. Cantarovich M, Metrakos P, Barkun JS, Giannetti N, Cecere R, Tchervenkov JI. Improvement of acute renal dysfunction after solid organ transplantation during calcineurin inhibitor holiday under anti-CD25 monoclonal antibody coverage. Transplant 2001, Chicago, IL, May 2001.

84. Loertscher R, Tremblay F, Tchervenkov JI, Metrakos P, Meterissian S. The effect of modern immunosuppression on the development and behavior of post-transplant cancers in kidney transplant recipients. Transplant 2001, Chicago, IL, May 2001.

85. Greig P, Grant DR, Kneteman N, McAlister V, Roy A, Scudamore C, Tchervenkov JI, Wall W, Yoshida E. Long term results of early steroid withdrawal following liver transplantation. Transplant 2001, Chicago, IL, May 2001.

Page 32: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

86. Cantarovich M, Barkun J, Metrakos P, Deschênes M, Tchervenkov JI. Effectiveness of the combination of mycophenolate mofetil and minimal dose cyclosporine microemulsion in long-term liver transplant patients with renal dysfunction. Canadian Society of Transplantation. Lake Louise, March 2001. 2001 a Transplant Odyssey. Istanbul, Aug 20-23, 2001

87. Grieg P, Grant D, Kneteman N, McAlister V, Roy A, Scudamore C, Tchervenkov JI, Wall W, Whoshida E, Moratta P, Peltekian K. Improved cardiovascular risk profile with tacrolimus and early steroid withdrawal following liver transplantation. 2nd International Congress on Immunosuppression, San Diego, CA, 2001.

88. Di Carlo A, Tector AJ, Tan M, Liu S, Soderland C, Metrakos P, Tchervenkov JI. Complement inactivation does not attenuate endothelial cell activation in pig-to-human liver xenotransplant. Surgical Forum (American College of Surgeons), October 2001.

89. DiCarlo A, Tchervenkov, J. Complement inactivation or depletion of GAL XNA does not abrogate the transcription of early growth response factor – 1 (EGR-1) in a model of pig-to-human liver xenotransplantation. VI Congress of the International Xenotransplantation Association, Sept 2001.

90. Tzimas G, Barkun J, Tchervenkov J, Deschenes M, Alpert E, Metrakos P. The impact leukoreduction on acute rejection in liver transplant recipients. Canadian Society of Transplantation, Mt-Tremblant, QC, March 2002.

91. Tzimas G, Barkun J, Tchervenkov J, Deschenes M, Alpert E, Metrakos P. The impact of leukoreduction on acute rejection on liver transplant recipients. American Transplant Congress, Washington, April 2002

92. Cantarovich M, Barkun JS, Metrakos P, Deschenes M, Alpert E, Tchervenkov JI. Anti-thymocyte globulin induction allows delayed introduction of calcineurin inhibitors with a low rejection rate in liver transplant patients with post-operative acute renal failure requiring dialysis. American Transplant Congress, Washington DC, April 2002.

93. Tzimas G, Tchervenkov J, Barkun J, Metrakos P, Deschenes M, Alpert E, Cantarovich M. Effectiveness of the combination of mycophenolate mofetil and minimal dose Cyclosporine micro-emulsion in long-term liver transplant patients with renal dysfunction. XIX International Congress of the Transplantation Society, Miami August 2002.

94. Tchervenkov JI, Barkun J, Metrakos P, Alpert E, Cantarovich M, Tzimas G, DiCarlo A, Hayati H, Fernandez M, Deschenes m. Comparison of interferon alpha 2B and Lamiduvine in preventing a recurrence of hepatitis B after liver transplantation. XIX International Congress of the Transplantation Society, Miami August 2002.

95. Tchervenkov JI, Barkun JS, Metrakos P, Alpert E, Cantarovich M, Tzimas G, Di Carlo A, Hayati H, Fernandez M, Deschenes M. Risk factors determining long-term survival in liver transplantation for hepatitis C. American Transplant Congress, Washington DC, April 2002.

Page 33: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

96. Di Carlo A, Tan M, Liu S, Tector AJ, Metrakos P, Tchervenkov JI. Human serum induces endothelial activation that is independent of complement and anti--Gal antibodies. American Transplant Congress, Washinton DC, April 2002.

97. Tchervenkov JI, Barkun JS, Metrakos P, Alpert E, Cantarovich M, Tzimas G, Di Carlo A, Hayati H, Fernandez M, Deschenes M. Comparison of Interferon Alpha 2B and Lamivudine in preventing recurrence of Hepatitis B after liver transplantation. Accepted for presentation at the XIX International Congress of the Transplantation Society, Miami FL, August 2002.

98. Cantarovich M, BarkunJ, Deschenes M, Metrakos P, Alpert E, Wong P, Fernandez M, Tchervenkov JI. Predictors of long-term renal function after liver transplantation. Canadian Society of Transplantation, Lake Louise, AB, 2003

99. Barkun J, Metrakos P, Cantarovich M, Tzimas G, Deschenes M, Alpert E, Paraskevas S, Tchervenkov, JI. Do Biliary Endoprotheses Decrease the biliary Complication Rate after Liver Transplantation? Canadian Society of Transplantation, Lake Louise, AB 2003

100. Barkun J, Metrakos P, Cantarovich M, Tzimas G, Deschenes M, Alpert E, Paraskevas S, Tchervenkov, JI. Do Biliary Endoprotheses Decrease the biliary Complication Rate after Liver Transplantation? American Trasnsplant Congress, Washington, June 2003.

101. Cantarovich M, Barkun J, Metrakos P, Deschenes M, Alpert E, Fernandez M, Tchervenkov JI. Early renal dysfunction post-liver transplant is not associated with progressively deteriorating long-term renal function. American Transplant Congress, Washington, June 2003

102. Cantarovich M, Barkun J, Metrakos P, Deschenes M, Alpert E, Fernandez M, Tchervenkov JI. Early renal dysfunction post-liver transplant is not associated with progressively deteriorating long-term renal function. International Liver Transplant Society, Barcelona, Spain June 2003.

103. Tchervenkov JI, Barkun J, Cantarovich M, Tzimas G, Paraskevas S, Deschenes M, Fernandez M, Metrakos P. The impact of slightly reduced renal function and delayed introduction of calcineurin inhibitors in orthotopic liver transplantation. International Liver Transplantation Society, Barcelona, Spain, 2003

104. Cantarovich M, Barkun J, Metrakos P, DiCarlo A, Deschenes M, Alpert E, Tchervenkov JI. Anti-thymocyte globulin-induction allows delayed initiation of calcineurin inhibitors with a low rejection rate on liver transplant patients with low rejection rate in liver transplant patients with post-operative renal dysfunction. International Liver Transplantation Society, Barcelona, Spain 2003.

105. Metrakos P, WexlerM, Tchervenkov JI, Barkun J, Valenti D, Alpert E, Deschenes M. Carboplatin chemoembolization of hepatomas prior to liver transplantation. A pilot study. International Liver Transplantation Society, Barcelona, Spain 2003.

Page 34: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

106. Tzimas G, Barkun J, Metrakos P, Deschenes M, AlpertE, Tchervenkov JI, Cantarovich M. Clinical benefits of varying doses of sirolimus in long-term heart transplant patients. International Liver Transplant Society, Barcelona, Spain 2003

107. Barkun J, Metrakos P, Cantarovich M, Tzimas G, Deschenes M, Alpert E, Paraskevas S, Tchervenkov JI. Do biliary endoprosthesis decrease the biliary complication rate after OLTx? International Liver Transplantation Society, Barcelona, Spain 2003 - poster

108. Tchervenkov JI, Barkun J, Resultats de divers traitements immunosuppresseurs pour patients porteurs d’hepatite C – resultants a 10 ans. Societe quebecoise de transplantation, Ottawa, ON Oct 2003

109. Tchervenkov JI, Barkun J, Cantarovich M, Tzimas G, Paraskevas S, Deschenes M, Fernandez M, Metrakos P. The impact of slightly reduced renal function and delayed introduction of calcineurin inhibitors in orthotopic liver transplantation. Canadian Society of Transplantation, Lake Louise, AB 2003

110. Rochon C, Metrakos P, Tchervenkov JI, Deschenes M, Alpert E, Fernandez M, Paraskevas S, Stein L, Barkun J. Endoscopic stenting as first line in duct of Lushka leak after choledochocystic anastomosis in 2 cases of liver transplantation. Canadian Transplant Congress, Mont-Tremblant, QC 2004.

111. Cantarovich M, Tchervenkov JI, Metrakos P, Paraskevas S, Barkun J, Magel R, Deschenes M, Wong P, Fontaine G, Besner G. Differences in pharmacokinetic profiles between long-term liver and kidney/pancreas transplant patients receiving maintenance tacrolimus and mycophenolate mofetil. Canadian Society of Transplantation, Mont-Tremblant, QC Feb 2004.

112. Bergman S, Feldman LS, Carli F, Anidjar, Metrakos P, Tchervenkov J, Paraskevas S, Klassen D, Vassiliou M, Andrew C, Stanbridge D, Fried G. Convalescence after laparoscopic live donor nephrectomy. American Transplant Congress, Boston, MA May 2004.

113. Cantarovich M, Tchervenkov J, Giannetti N, Metrakos P, Barkun J, Paraskevas S, Mangel R, Sciff J, Fontaine G, Besner J-G. Variability of cyclosporine microemulsion C2 levels in fasting and fed organ transplant patients. American Transplant Congress, Boston, MA May 2004.

114. Cantarovich M, Barkun J, Tchervenkov J, Paraskesvas S, Sciff J, Mangel R, Deschenes M, Fontaine G, Coursol C, Metrakos P. Accuracy of cimetidine-corrected serum creatinine, creatinine clearance and calculated creatinine clearance to assess the glomerular filtration rate in long-term kidney pancreas and liver tranplant patients. American Transplant Congress, Boston, MA May 2004.

115. Cantarovich M, Tchervenkov J, Metrakos P, Paraskevas S, Barkun J, Mangel R, Deschenes M, Schiff J, Wong P, Fontaine G, Besner J. Differences in Pharmacokinetic profiles between long-term

Page 35: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

liver and kidney/pancreas transplants receiving maintenance tacrolimus and mycophenolate mofetil. American Transplant Congress, Boston, MA May 2004

116. Tchervenkov J, Cantarovich M, Paraskevas S, Fernandez M, Baran D, Mangel R, Schiff J, Lipman M, Metrakos P. Cadaveric renal transplantation and expanded criteria donors: Should we reassess their use? Accepted for presentation at the American Transplant Congress, Boston MA, May 2004.

117. Tchervenkov J, Cantarovich M, Paraskevas S, Fernadez M, Baran D, Mangel R, Schiff J, Lipman M, Horton P, Metrakos P. Cadaveric Renal Transplantation and Expanded Criteria Donors: Should we reassess their use? Oral presentation at XX International Congress of the Transplantation Society, Vienna, Austria, September 2004.

118. S Bergman, LS Feldman, F Carli, M Anidjar, PP Metrakos, JI Tchervenkov, S Paraskevas, DKlassen, CG Andrew, MC Vassiliou, DD Stanbridge and GM Fried. Surgical recovery following laparoscopic live donor nephrectomy, Canadian Association of General Surgeons, Ottawa, ON, September, 2004.

119. J Martinie, M Fernandez RN, P Chaudhury, P Horton, T Znajada, J Tchervenkov, P Metrakos. Orthotopic Liver Transplantation for Hepatocellular Carcinoma in 89 patients: A Single Center Experience. Poster presentation at Canadian Transplant Congress, Banff AB, Mar 2005.

120. P.J.Horton, C.Rochon, P.Chaudhury, J.B.Martinie, T.L.Znajda, M.Fernandez, J.Barkun,P.Metrakos, J.Tchervenkov. Antithymocyte Globulin (ATG) Induction Therapy in Hepatitis-C Positive Liver Transplant Recipients is Associated with Excellent Long Term Survival. Oral Presentation at Canadian Transplant Congress, Banff AB, Mar 2005.

121. P.J.Horton, P.Chaudhury, J.B.Martinie, T.L.Znajda, C.Rochon, M.Fernandez, M. Deschenes, P. Metrakos, J.S. Barkun, M. Cantarovich, J.Tchervenkov. Interferon Superior to Lamivudine at Preventing Heptatis-B Recurrence in Liver Transplant Recipients. Poster presentation at Canadian Transplant Congress, Banff AB, Mar 2005.

122. P.J.Horton, J.B.Martinie, C.Rochon, P.Chaudhury, T.L.Znajda, M.Fernandez, M.Deschenes, J.S.Barkun, P.Metrakos, M.Cantarovich, J.Tchervenkov. Incidence of chronic renal failure in liver transplant patients receiving Thymoglobulin induction and delayed introduction of calcineurin inhibitors. Poster presentation at Canadian Transplant Congress, Banff AB, Mar 2005.

123. A Kapoor, C Cardella, G Knoll, J Tchervenkov, A House & Direct Study Group. 3 Month interim analysis of a prospective, randomized, multicenter trial to compare the incidence of new onset diabetes mellitus (NODM) and glucose metabolism (GM) on patients receiving cyclosporine microemulsion (CSA-ME) versus tacrolimus (TAC) after de novo kidney transplantation. Poster presentation at Canadian Transplant Congress, Banff AB, Mar 2005.

124. P Horton, J Barkun, M Cantarovich, C Rochon, M Fernandez, P Metrakos, J Tchervenkov. Over 14 years Experience with Antithymocyte Globulin (ATG) Induction Therapy in Hepatitis C positive

Page 36: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

Liver Transplant Recipients. Oral Presentation at American Transplant Congress, Seattle WA, May 2005.

125. J Tchervenkov, J Barkun, PHorton, M Fernandez, M Cantarovich, M Deschenes, P Metrakos. Early Predictors of Patient Survival after Liver Transplantation: Not all MELD Scores are created equal? Oral Presentation at American Transplant Congress, Seattle WA, May 2005.

126. P Horton, J Barkun, C Rochon, M Fernandez, P Metrakos, J Tchervenkov. Predictors of Graft Outcome in Hepatitis C Positive Liver Transplant Recipients. Poster Presentation at American Transplant Congress, Seattle WA, May 2005.

127. P Horton, J Barkun, C Rochon, M Fernandez RN, M Deschenes, P Metrakos, M Cantarovich, J Tchervenkov. Twelve years Experience Preventing Hepatitis B Recurrence with Interferon and Hepatitis B-Immunoglobulin (HBIG) in Liver Transplant Recipient. Poster Presentation at American Transplant Congress, Seattle WA, May 2005.

128. M. Cantarovich, J. Tchervenkov, S. Paraskevas, D. Keith, P. Horton, D. Baran, R. Mangel, M. Lipman, M. Fernandez and P. Metrakos. Anti-Thymocyte Globulin Induction and Delayed Introduction of Calcineurin Inhibitors results in Excellent Outcome in Renal Transplant Patients with Delayed Graft Function. Poster Presentation at American Transplant Congress, Seattle WA, May 2005.

129. M. Cantarovich, P. Horton, J. Tchervenkov, J. Barkun, M. Deschênes, M. Fernandez and P. Metrakos. Anti-Thymocyte Globulin Induction and Delayed Introduction of Calcineurin Inhibitors improves survival and results in a low requirement for Chronic Dialysis in Liver Transplant Recipients with Post-Operative Renal Dysfunction. Oral Presentation at American Transplant Congress, Seattle WA, May 2005.

130. M. Cantarovich, S. Paraskevas, D. Keith, M. Lipman, R. Mangel, G. Fontaine, P. Metrakos and J. Tchervenkov. Optimal Time Points to Assess the Area-Under-the-Curve in Long-term Kidney Transplant Patients on Mycophenolate Mofetil and either Tacrolimus or Cyclosporine Microemulsion Maintenance Immunosuppression. Poster Presentation at American Transplant Congress, Seattle WA, May 2005.

131. M. Cantarovich, S. Paraskevas, D. Keith, M. Lipman, R. Mangel, G. Fontaine, P. Metrakos and J. Tchervenkov. Differences in Pharmacokinetic Profiles between Long-term Kidney/Pancreas and Non-Diabetic Kidney Transplant Patients on Tacrolimus and Mycophenolate Mofetil. Poster Presentation at American Transplant Congress, Seattle WA, May 2005.

132. P Horton, J Barkun, M Cantarovich, C Rochon, M Fernandez, P Metrakos, J Tchervenkov. Experience with Antithymocyte globulin (ATG) induction therapy in hepatitis C positive liver transplant recipients over 14 years. Oral Presentation at 12th Congress European Society of Organ Transplantation (ESOT), Geneva, Switzerland, Sept 2005.

Page 37: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

133. P Horton, J Barkun, C Rochon, M Fernandez, P Metrakos, J Tchervenkov. Predictors of graft outcome in hepatitis C liver recipients. Oral Presentation at 12th Congress European Society of Organ Transplantation (ESOT), Geneva, Switzerland, Sept 2005.

134. J Martinie, P Horton, P Chaudhury, T Znajda, J Barkun, P Metrakos, J Tchervenkov. Liver transplantation for hepatocellular carcinoma outside Milan criteria: A single centre experience. Oral Presentation at 12th Congress European Society of Organ Transplantation (ESOT), Geneva, Switzerland, Sept 2005.

135. P Horton, J Barkun, C Rochon, M Fernandez, M Deschenes, P Metrakos, M Cantarovich, J Tchervenkov. Twelve years experience preventing hepatitis B recurrence with Interferon and hepatitis B immunoglobulin (HBIG) in liver transplant recipients. Poster Presentation at 12th

Congress European Society of Organ Transplantation (ESOT), Geneva, Switzerland, Sept 2005.

136. J. Tchervenkov, P. Chaudhury, M. Fernandez, J. Barkun, M. Cantarovich, P. Ghali, P. Metrakos, M. Deschenes. Long-term results with pre-tranpslant hepatitis B viral load reduction in liver transplantation: Comparison between Lamivudine and Interferon-Alpha 2B (IFN). Oral Presentation at Canadian Transplant Congress, Tremblant, QC Canada, March 2006.

137. P Chaudhury, P Horton, P Metrakos, J Barkun, M Fernandez, P Ghali, M Deschenes, J Tchervenkov. Outcomes of Liver Transplantation in Hepatitis C Positive Patients with Hepatocellular Carcinoma. Poster Presentation at Canadian Transplant Congress, Tremblant, QC Canada, March 2006.

138. A Alam, M Cantarovich, R Mangel, J Tchervenkov, P Metrakos, S Paraskevas. Pancreas Transplant Alone as compared with Pancreas-After Kidney Transplant on the Progression of Chronic Kidney Disease: A single-center experience. Poster Presentation at Canadian Transplant Congress, Tremblant, QC Canada, March 2006.

139. M Cantarovich, J Tchervenkov, J Barkun, M Deschenes, P Ghali, G Fontaine, P Metrakos. Improvement of Acute Renal Dysfunction in Liver transplant Patients with a Calcineurin Inhibitor “Holiday” under Anti-CD25 Monoclonal Antibody Coverage. Poster Presentation at Canadian Transplant Congress, Tremblant, QC Canada, March 2006.

140. M Cantarovich, J Tchervenkov, J Barkun, J-P Routy, M Deschenes, P Ghali, G Fontaine, P Metrakos. Calcineurin Inhibitor Substitution (“Retirement”) with Daclizumab: A novel strategy in long-term Liver Transplant Patients with Progressive Renal Dysfunction. Poster Presentation at Canadian Transplant Congress, Tremblant, QC Canada, March 2006.

141. M Cantarovich, N Giannetti, J Tchervenkov, E Cyr, R Chartier, D Centric, G Fontaine, R Cecere. Effectiveness of Post-Transplant Prophylaxis with Anti-Hepatitis B Virus (HBV) Immunoglobulin in Heart Transplant Patients with Anti-HBV Core Antibodies and in Recipients of Organs from HBV Core Antibody Positive Donors. Poster Presentation at Canadian Transplant Congress, Tremblant, QC Canada, March 2006.

Page 38: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

142. JA Davidson, J Tchervenkov, J Barkun, MD deB. Edwards, M Deschenes, P Gahli, G Fontaine, P Metrakos, M Cantarovich. Impact of Cimetidine Administration on the Ability of Equations to Effectively Predict Changes in Glomerular Filtration Rate in Long-Term Liver Transplant Patients. Poster Presentation at Canadian Transplant Congress, Tremblant, QC Canada, March 2006.

143. P Horton, J Barkun, P Chaudhury, M Fernandez, P Metrakos, J Tchervenkov. Liver Transplantation for Hepatocellular Carcinoma Outside Milan Criteria: A Single Center Experience. Poster Presentation at Canadian Transplant Congress, Tremblant, QC Canada, March 2006.

144. P Horton, J Barkun, P Chaudhury, M Fernandez, P Metrakos, J Tchervenkov. Predictors of Graft Outcome in Hepatitis –C Positive Liver Transplant Recipients. Poster Presentation at Canadian Transplant Congress, Tremblant, QC Canada, March 2006.

145. P Chaudhury, P Horton, P Metrakos, J Barkun, M Fernandez, P Ghali, M Deschenes, J Tchervenkov. Hepatitis C and the Milan Criteria. Poster Presentation at World Transplant Congress, Boston, MA, July 2006.

146. Tchervenkov J., Barkun J., Deschenes M., Gahali P., Fernandez M., Cantarovich M., Chaudhury P., Metrakos P. Viral Load Reduction Pre-Transplant for Hepatitis B in Liver Transplantation: Long term results of Interferon –Alpha 2B versus Lamivudine. Is it time for Re-Evaluation? Oral Presentation at World Transplant Congress, Boston, MA, July 2006.

147. J Tchervenkov, S Paraskevas, M Cantarovich, D Keith, D Baran, M Fernandez, P Metrakos. Cadaveric Renal Transplantation: To Improve Long Term Results we should concentrate on Reducing Delayed Graft Function. Poster Presentation at World Transplant Congress, Boston, MA, July 2006.

148. J Tchervenkov. “Alpha-Gal antibody production by human Blymphocytes is T lymphocyte dependent: Imlivation for strategies against antibody medicated rejection”. Oral Presentation at Canadian Transplant Congress, Banff, AB, March 2007.

149. J. Tchervenkov. “Improved Actual Renal Allograft Surviving using Tacrolimus and Micofenolate Mofetil: The impact is on kidneys with delayed graft function”. Poster Presentation at Canadian Transplant Congress, Banff, AB, March 2007.

150. D Kandeva, J Tchervenkov. B Lymphocyte Require T Lymphocyte Help to Proliferate. Poster Presentation at Canadian Transplant Congress, Mont Tremblant, QC March 2008.

151. R Tavana, J Tchervenkov. Increased Expression of IL-21 Receptor on B-lymphocytes of Highly Sensitized Renal Transplant Recipients. A possible target for B-lymphocyte antibody production in sensitized renal recipients. Poster Presentation at Canadian Transplant Congress, Mont Tremblant, QC March 2008.

152. Vrochides D, Hassanain M, Metrakos P, Tchervenkov J, Chaudhury P, Cantarovich M, Paraskevas S. ‘Prolonged lymphopenia after anti-thymocyte globulin induction is not associated with

Page 39: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

increased graft survival in pancreas transplant recipients. Poster Presentation at Canadian Transplant Congress Meeting, Mont Tremblant, QC, Feb 2008.

153. Vrochides D, Hassanain M, Barkun J, Tchervenkov J, Chaudhury P, Canatrovich M, Deschenes M, Wong P, Ghali P, Metrakos P. ‘Prediction of postoperative mortality and long-term survival after liver transplantation, based on preoperative parameters. Poster Presentation at Canadian Transplant Congress Meeting, Mont Tremblant, QC, Feb 2008.

154. Vrochides D, Hassanain M, Metrakos P, Tchervenkov J, Chaudhury P, Cantarovich M, Paraskevas S. ‘Persistant monocyte depletion does not improve graft survival after liver pancreas alone and kidney transplants’. Poster Presentation at Canadian Transplant Congress Meeting, Mont Tremblant, QC, Feb 2008.

155. Vrochides D, Hassanain M, Barkun J, Tchervenkov J, Chaudhury P, Cantarovich M, Deschenes M, Wong P, Ghali P, Metrakos P. ‘Selection of liver transplant recipients for the treatment of HCC based on adjustable preoperative criteria with a pre-determined, center specific, five-year patient survival taget. Poster Presentation at Canadian Transplant Congress Meeting, Mont Tremblant, QC, Feb 2008.

156. Vrochides D, Hassanain M, Metrakos P, Tchervenkov J, Chaudhury P, Cantarovich M, Paraskevas S. ‘Allocation of non-ecd renal grafts to older patients results in loss of functioning graft-years secondary to recipients’ lower life expectancy’. Highlighted Poster Presentation at Canadian Transplant Congress Meeting, Mont Tremblant, QC, Feb 2008.

157. Vrochides D, Hassanain M, Barkun J, Tchervenkov J, Chaudhury P, Deschenes M, Wong P, Ghali P, Metrakos P. ‘Baseline hepatic arterial Doppler increases patient but not graft survival in orthotopic liver transplantation’. Poster Presentation at Canadian Transplant Congress Meeting, Mont Tremblant, QC, Feb 2008.

158. Canatarovich M, Paraskevas S, Chaudhury P, Keith D, Baran D, Hassanian, Fernandez M, Mangel R, Lipman M, Metrakos P, Tchervenkov J, Ladouceur M. ‘ Estimated GFR after treatment of acute rejection: A surrogate marker for long-term graft survival after kidney transplantation’. Poster Presentation at Canadian Transplant Congress Meeting, Mont Tremblant, QC, Feb 2008.

159. Boutros M, Neville A, Vrochides D, Paraskevas S, Chaudhury P, Metrakos P, Tchervenkov J, Fernandez M, Cantarovich M, Deschenes M, Ghali P, Wong P, Barkun J. ‘A Ramdomized trial of intra-operative biliary stent at Orthotopic liver transplantation’. Oral Presentation at A Canadian Transplant Congress Meeting, Mont Tremblant, QC, Feb 2008.

160. Tchervenkov J, Cantarovich M, Fernandez M, Paraskevas S, Baran D, Matthews K, Metrakos P. ‘Delayed graft function has an equally bad impact on deceased donor renal graft survival in both standard criteria donors and expanded criteria donors’. Poster Presentation at American Transplant Congress Meeting, Toronto, ON, May 2008.

Page 40: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

161. Tavana R, Kandeva D, Lui S, Tchervenkov J. ‘Expression of IL-21 receptor on B Lymphocytes of Highly Sensitized Patients is Up-Regulated: A potential target for B cell IgG Production’. Oral Presentation at American Transplant Congress Meeting, Toronto, ON, May 2008.

162. Boutros M, Neville A, Vrochides D, Paraskevas S, Chaudhury P, Metrakos P, Tchervenkov J, Fernandez M, Cantarovich M, Deschenes M, Ghali P, Wong P, Barkun J. ‘A Ramdomized trial of intra-operative biliary stent at Orthotopic liver transplantation’. Oral Presentation at American Transplant Congress Meeting, Toronto, ON, May 2008.

163. Tchervenkov J, ‘The impact of delayed graft function on actual graft survival is equally bad in deceased donor kidney transplants from expanded criteria donors and standard criteria donors’. Poster Presentation at the XXII International Congress of The Transplantation Society Meeting’, Sydney, Australia, August 2008.

164. Tchervenkov J, ‘Recovery of Graft Function Early Post Transplant Determines Long-Term Graft Survival in Deceased Donor (DD) Renal Transplants’. Poster Presentation at the XXII International Congress of The Transplantation Society Meeting’, Sydney, Australia, August 2008.

165. Tavana R, Lui S, Tchervenkov J. ‘Interleukin-21 receptor on B-lymphocytes in Highly Sensitized Renal Transplant Recipients: a potential target for desensitization.’ Oral Presentation at the XXII International Congress of The Transplantation Society Meeting’, Sydney, Australia, August 2008.

166. Lui S, Tchervenkov J. ‘T-cell is essential in memory B-cell alpha-gal xenoanitbody production: Implications for ABO incompatible and xenotransplantation.’ Oral Presentation at the XXII International Congress of The Transplantation Society Meeting’, Sydney, Australia, August 2008.

167. Kandeva T, Tchervenkov J. ‘B Cell Proliferation After Á-Gal Exposure Requires The Presence Of Activated T Helper Cells.’ Oral Presentation at the XXII International Congress of The Transplantation Society Meeting’, Sydney, Australia, August 2008.

168. T Kandeva, S Lui, J Tchervenkov. ‘Tcell help is essential in the context of B cell proliferation and antigal antibody production’. Accepted for Oral Presentation at the Canadian Society Transplant Annual Scientific Meeting. Banff, AB, Mar 2009.

169. Hassanain M, Metrakos P, Boutros M, Barkun J, Fernandez M, Cantarovich M, Paraskevas S, Chaudhury P, Tchervenkov J. ‘Predictors of clinically severe hepatitis c recurrence after liver transplantation.’ Accepted for Oral Presentation at the Canadian Society Transplant Annual Scientific Meeting. Banff, AB, Mar 2009.

170. T Kandeva, S Lui, J Tchervenkov. ‘B Cell Response to the Abo-Blood Group Antigen and to the Xenoantigen A-Gal is T Cell dependent and similar’. Accepted for Poster Presentation at the Canadian Society Transplant Annual Scientific Meeting. Banff, AB, Mar 2009

171. Hassanain M, Metrakos P, Boutros ML, Barkun J, Fernandez M, Cantarovich M, Paraskevas S, Chaudhury P, Tchervenkov J. ‘Liver - Complications, Recurrent Disease, Hepatitis and

Page 41: Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM … · Jean I. Tchervenkov, MD, FRCSC, FACS CURRICULUM VITAE IDENTIFICATION OFFICE ADDRESS: Royal Victoria Hospital Department of Surgery

Jean I. Tchervenkov Last Updated February 15, 2010

Retransplantation’. Accepted for Poster Presentation at American Transplant Congress Meeting, Boston, MA, May 2009.

172. M Hassanain, J Tchervenkov, J Barkun, S Paraskevas, P Chaudhury, P Metrakos. ‘Postoperative Liver Transplant Function Score Can Predict Short and Long-Term Surgical Outcomes’. Accepted for Poster Presentation at American Transplant Congress Meeting, Boston, MA, May 2009.

173. T Kandeva, MSc, S Liu, MSc., J Tchervenkov, MD. ‘B cell response to the ABO-blood group antigen and to the xenoantigen -Gal is T cell-dependent and similar’. Accepted for Poster Presentation at American Transplant Congress Meeting, Boston, MA, May 2009.

174. Hassanain M, Metrakos P, Boutros M, Barkun J, Fernandez M, Cantarovich M, Paraskevas S, Chaudhury P, Tchervenkov J. ‘Predictors of clinically severe hepatitis c recurrence after liver transplantation.’ Accepted for Oral Presentation at the Canadian Society Transplant Annual Scientific Meeting. Banff, AB, Mar 2009

175. M Hassanain, MD, S Paraskevas, MD, P Chaudhury, MD, M Cantarovich, MD, P Metrakos, MD, J Tchervenkov, MD. ‘Early Predictors of Graft Survival in Cadaveric Renal Transplantation’. Accepted for Poster Presentation at American Transplant Congress Meeting, Boston, MA, May 2009.

176. M Hassanain, J Tchervenkov, J Barkun, S Paraskevas, P Chaudhury, P Metrakos. ‘Postoperative Liver Transplant Function Score Can Predict Short and Long-Term Surgical Outcomes’. Accepted for Poster Presentation at International Liver Transplantation Society Congress Meeting, New York, NY, July 2009.